{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "174833e5",
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "import os\n",
    "script_dir = os.getcwd()\n",
    "root_dir = os.path.join(os.path.dirname(os.path.abspath(script_dir)))\n",
    "sys.path.append(os.path.join(os.path.dirname(os.path.abspath(script_dir))))\n",
    "\n",
    "import json\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "from utils.io import load_object, save_object\n",
    "import requests\n",
    "from collections import Counter\n",
    "import spacy\n",
    "import faiss\n",
    "from openai import OpenAI\n",
    "from utils.embedding import get_context_db\n",
    "from dotenv import load_dotenv\n",
    "import random\n",
    "import math\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "1f8b0965",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/home/helenajun/rag-llm-cancer-paper'"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "os.chdir(root_dir)\n",
    "os.getcwd()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "f78c1902",
   "metadata": {},
   "outputs": [],
   "source": [
    "#split ranges for testing on small batches\n",
    "def split_ranges(max_int, num_ranges, samples=None, seed=42):\n",
    "    random.seed(seed)\n",
    "    step = math.ceil(max_int / num_ranges)\n",
    "    ranges = [(i*step+1, min((i+1)*step, max_int)) for i in range(num_ranges)]\n",
    "    \n",
    "    if samples is None:\n",
    "        return ranges\n",
    "    \n",
    "    # split samples evenly across ranges\n",
    "    n_per_range = samples // num_ranges\n",
    "    remainder = samples % num_ranges\n",
    "    \n",
    "    result = []\n",
    "    for i, r in enumerate(ranges):\n",
    "        count = n_per_range + (1 if i < remainder else 0)\n",
    "        result.extend(random.randint(r[0], r[1]) for _ in range(count))\n",
    "    \n",
    "    return result\n",
    "\n",
    "\n",
    "# function to subset FDA statements\n",
    "def subset_db_statements(statements, organization='fda'):\n",
    "    # subset statements\n",
    "    subset=[statement for statement in statements if statement['reportedIn'][0]['organization']['id'] == organization]\n",
    "    return subset\n",
    "\n",
    "# function to ensure list\n",
    "def ensure_list(x):\n",
    "    return x if isinstance(x, list) else [x]\n",
    "\n",
    "# function to extract biomarker from statement\n",
    "def extract_biomarker_info(stmt):\n",
    "    # extract biomarkers from the statement\n",
    "    biomarkers_list = []\n",
    "    for i in range(len(stmt['proposition']['biomarkers'])):\n",
    "        biomarker = stmt[\"proposition\"][\"biomarkers\"][i][\"name\"]\n",
    "        extensions_dict = {item['name']: item['value'] for item in stmt['proposition']['biomarkers'][i]['extensions']}\n",
    "        presence = extensions_dict.get('present', '')\n",
    "        biomarkers_list.append(biomarker)\n",
    "        \n",
    "        # extract presence information\n",
    "        if presence == True:\n",
    "            biomarker += \" [present]\"\n",
    "        else:   \n",
    "            biomarker += \" [not present]\"\n",
    "        if i == 0:\n",
    "            biomarkers_str = biomarker\n",
    "        else:\n",
    "            biomarkers_str += f\", {biomarker}\"\n",
    "    \n",
    "    extracted_info = {\n",
    "        \"str\": biomarkers_str, \n",
    "        \"list\": biomarkers_list\n",
    "    }\n",
    "    \n",
    "    return extracted_info\n",
    "\n",
    "\n",
    "# function to extract therapy info from statement\n",
    "def extract_therapy_info(stmt):\n",
    "    # extract membership operator\n",
    "    obj = stmt.get('proposition', {}).get('objectTherapeutic', {})\n",
    "    operator = obj.get('membership_operator', None)\n",
    "    \n",
    "    # extract therapy approach, type, and names\n",
    "    if operator == 'AND':\n",
    "        approach = 'Combination therapy'\n",
    "        therapy_strategyList = []\n",
    "        therapy_typeList = []\n",
    "        for therapy in obj.get('therapies', []):\n",
    "            extensions_dict = {item['name']: item['value'] for item in therapy['extensions']}\n",
    "            therapy_strategyList.extend(ensure_list(extensions_dict['therapy_strategy']))\n",
    "            therapy_typeList.extend(ensure_list(extensions_dict['therapy_type']))\n",
    "        drugList = [drug.get('name', None) for drug in obj.get('therapies', [])]\n",
    "        \n",
    "    else:\n",
    "        approach = 'Monotherapy'\n",
    "        therapy_strategyList = []\n",
    "        therapy_typeList = []\n",
    "        extensions_dict = {item['name']: item['value'] for item in obj['extensions']}\n",
    "        therapy_strategyList.extend(ensure_list(extensions_dict['therapy_strategy']))\n",
    "        therapy_typeList.extend(ensure_list(extensions_dict['therapy_type']))\n",
    "        drugList = [obj.get('name', None)]\n",
    "    \n",
    "    # sanity check for drugList\n",
    "    if any(d is None for d in drugList):\n",
    "        raise ValueError(f\"Found None in drugList for statement {stmt['id']}\")\n",
    "    \n",
    "    drug_str = \" + \".join([d for d in drugList if d is not None])\n",
    "    therapy_strategy_str = \" + \".join([s for s in therapy_strategyList if s is not None])\n",
    "    therapy_type_str = \" + \".join([t for t in therapy_typeList if t is not None])\n",
    "    \n",
    "    extracted_info = {\n",
    "        \"str\": {\n",
    "            \"drug_str\": drug_str, \n",
    "            \"therapy_approach\": approach,\n",
    "            \"therapy_strategy_str\": therapy_strategy_str, \n",
    "            \"therapy_type_str\": therapy_type_str\n",
    "                }, \n",
    "        \"list\": {\n",
    "            \"drugList\": drugList, \n",
    "            \"therapy_approach\": approach,\n",
    "            \"therapy_strategyList\": therapy_strategyList, \n",
    "            \"therapy_typeList\": therapy_typeList\n",
    "            }\n",
    "        }\n",
    "    \n",
    "    return extracted_info\n",
    "\n",
    "\n",
    "# function to flatten statement into summary text to include in context\n",
    "def flatten_statements(stmt: dict) -> str:\n",
    "    \n",
    "    statement_id = stmt.get(\"id\")\n",
    "    \n",
    "    # approval status\n",
    "    approval_status = stmt.get(\"reportedIn\", [{}])[0].get(\"subtype\", \"None\")\n",
    "    approval_org = stmt.get(\"reportedIn\", [{}])[0].get(\"organization\", {}).get(\"id\", \"Unknown organization\")\n",
    "    approval_url = stmt.get(\"reportedIn\", [{}])[0].get(\"url\", \"Unknown URL\")\n",
    "    approval_date = stmt.get(\"reportedIn\", [{}])[0].get(\"publication_date\", \"Unknown date\")\n",
    "    \n",
    "    # description and indication\n",
    "    description = stmt.get(\"description\", \"None\")\n",
    "    indication = stmt.get(\"indication\", {}).get(\"indication\", \"None\")\n",
    "    \n",
    "    # cancer type\n",
    "    cancer_type = stmt.get(\"proposition\", {}).get(\"conditionQualifier\", {}).get(\"name\", \"Unknown cancer\")\n",
    "    \n",
    "    # biomarkers\n",
    "    biomarker = extract_biomarker_info(stmt)\n",
    "    \n",
    "    # therapy\n",
    "    therapy_info = extract_therapy_info(stmt)\n",
    "    \n",
    "    # create summary text\n",
    "    summary = (\n",
    "        f\"Indication: {indication}\\n\"\n",
    "        f\"Cancer type: {cancer_type}\\n\"\n",
    "        f\"Biomarkers: {biomarker['str']}\\n\"\n",
    "        f\"Therapy: {therapy_info['str']['drug_str']}\\n\"\n",
    "        f\"Therapy approach: {therapy_info['str']['therapy_approach']}\\n\"\n",
    "        f\"Therapy strategy: {therapy_info['str']['therapy_strategy_str']}\\n\"\n",
    "        f\"Therapy type: {therapy_info['str']['therapy_type_str']}\\n\"\n",
    "        f\"Description: {description}\\n\"\n",
    "        f\"Approval status: {approval_status} ({approval_org})\\n\"\n",
    "        f\"Approval url: {approval_url}\\n\"\n",
    "        f\"Publication date: {approval_date}\"\n",
    "    )\n",
    "    \n",
    "    # create row to add to dataframe\n",
    "    row = {\n",
    "        \"statement_id\": statement_id,\n",
    "        \"approval_status\": approval_status,\n",
    "        \"approval_org\": approval_org,\n",
    "        \"description\": description,\n",
    "        \"indication\": indication,\n",
    "        \"cancer_type\": cancer_type,\n",
    "        \"biomarker\": biomarker['list'],\n",
    "        \"therapy_drug\": therapy_info['list']['drugList'],\n",
    "        \"therapy_approach\": therapy_info['list']['therapy_approach'],\n",
    "        \"therapy_strategy\": therapy_info['list']['therapy_strategyList'],\n",
    "        \"therapy_type\": therapy_info['list']['therapy_typeList'],\n",
    "        \"approval_url\": approval_url,\n",
    "        \"publication_date\": approval_date,\n",
    "        \"context\": summary\n",
    "    }\n",
    "    \n",
    "    return summary, row\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "2a7aa18b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1784\n"
     ]
    }
   ],
   "source": [
    "statements = requests.get('https://api.moalmanac.org/statements').json()['data']\n",
    "print(len(statements))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "d83feec8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "642\n"
     ]
    }
   ],
   "source": [
    "fda_statements=subset_db_statements(statements, organization='fda')\n",
    "print(len(fda_statements))\n",
    "\n",
    "CACHE_FILE = \"db_version_cache.json\"\n",
    "def get_local_version():\n",
    "    if os.path.exists(CACHE_FILE):\n",
    "        with open(CACHE_FILE) as f:\n",
    "            return json.load(f).get(\"version\")\n",
    "    return None\n",
    "\n",
    "version=get_local_version()\n",
    "with open(f\"data/latest_db/fda_statements__{version}.json\", \"w\") as f:\n",
    "    json.dump(fda_statements, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "9e26281b",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(f\"data/latest_db/fda_statements__{version}.json\", \"r\") as f:\n",
    "    fda_statements = json.load(f)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "470a3e22",
   "metadata": {},
   "source": [
    "## Create synthetic queries and answers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "d13c612b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(642, 6)\n"
     ]
    },
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "statement_id",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "standardized_cancer",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "raw_cancer",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "modified_standardized_cancer",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "biomarker",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "therapy",
         "rawType": "object",
         "type": "unknown"
        }
       ],
       "ref": "b685afcc-fbc5-4dad-abca-acd335a2dc1e",
       "rows": [
        [
         "0",
         "0",
         "Invasive Breast Carcinoma",
         "early breast cancer",
         "early invasive breast carcinoma",
         "['HER2-negative', 'ER positive']",
         "['Tamoxifen', 'Abemaciclib']"
        ],
        [
         "1",
         "1",
         "Invasive Breast Carcinoma",
         "early breast cancer",
         "early invasive breast carcinoma",
         "['PR positive', 'HER2-negative']",
         "['Tamoxifen', 'Abemaciclib']"
        ],
        [
         "2",
         "2",
         "Invasive Breast Carcinoma",
         "early breast cancer",
         "early invasive breast carcinoma",
         "['PR positive', 'HER2-negative', 'ER positive']",
         "['Tamoxifen', 'Abemaciclib']"
        ],
        [
         "3",
         "3",
         "Invasive Breast Carcinoma",
         "advanced or metastatic breast cancer",
         "advanced or metastatic invasive breast carcinoma",
         "['HER2-negative', 'ER positive']",
         "['Anastrozole', 'Abemaciclib']"
        ],
        [
         "4",
         "4",
         "Invasive Breast Carcinoma",
         "advanced or metastatic breast cancer",
         "advanced or metastatic invasive breast carcinoma",
         "['PR positive', 'HER2-negative']",
         "['Anastrozole', 'Abemaciclib']"
        ]
       ],
       "shape": {
        "columns": 6,
        "rows": 5
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>statement_id</th>\n",
       "      <th>standardized_cancer</th>\n",
       "      <th>raw_cancer</th>\n",
       "      <th>modified_standardized_cancer</th>\n",
       "      <th>biomarker</th>\n",
       "      <th>therapy</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>early breast cancer</td>\n",
       "      <td>early invasive breast carcinoma</td>\n",
       "      <td>[HER2-negative, ER positive]</td>\n",
       "      <td>[Tamoxifen, Abemaciclib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>early breast cancer</td>\n",
       "      <td>early invasive breast carcinoma</td>\n",
       "      <td>[PR positive, HER2-negative]</td>\n",
       "      <td>[Tamoxifen, Abemaciclib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>early breast cancer</td>\n",
       "      <td>early invasive breast carcinoma</td>\n",
       "      <td>[PR positive, HER2-negative, ER positive]</td>\n",
       "      <td>[Tamoxifen, Abemaciclib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>advanced or metastatic breast cancer</td>\n",
       "      <td>advanced or metastatic invasive breast carcinoma</td>\n",
       "      <td>[HER2-negative, ER positive]</td>\n",
       "      <td>[Anastrozole, Abemaciclib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>advanced or metastatic breast cancer</td>\n",
       "      <td>advanced or metastatic invasive breast carcinoma</td>\n",
       "      <td>[PR positive, HER2-negative]</td>\n",
       "      <td>[Anastrozole, Abemaciclib]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   statement_id        standardized_cancer  \\\n",
       "0             0  Invasive Breast Carcinoma   \n",
       "1             1  Invasive Breast Carcinoma   \n",
       "2             2  Invasive Breast Carcinoma   \n",
       "3             3  Invasive Breast Carcinoma   \n",
       "4             4  Invasive Breast Carcinoma   \n",
       "\n",
       "                             raw_cancer  \\\n",
       "0                   early breast cancer   \n",
       "1                   early breast cancer   \n",
       "2                   early breast cancer   \n",
       "3  advanced or metastatic breast cancer   \n",
       "4  advanced or metastatic breast cancer   \n",
       "\n",
       "                       modified_standardized_cancer  \\\n",
       "0                   early invasive breast carcinoma   \n",
       "1                   early invasive breast carcinoma   \n",
       "2                   early invasive breast carcinoma   \n",
       "3  advanced or metastatic invasive breast carcinoma   \n",
       "4  advanced or metastatic invasive breast carcinoma   \n",
       "\n",
       "                                   biomarker                     therapy  \n",
       "0               [HER2-negative, ER positive]    [Tamoxifen, Abemaciclib]  \n",
       "1               [PR positive, HER2-negative]    [Tamoxifen, Abemaciclib]  \n",
       "2  [PR positive, HER2-negative, ER positive]    [Tamoxifen, Abemaciclib]  \n",
       "3               [HER2-negative, ER positive]  [Anastrozole, Abemaciclib]  \n",
       "4               [PR positive, HER2-negative]  [Anastrozole, Abemaciclib]  "
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import ast\n",
    "standardized_to_raw_mapping=pd.read_csv(\"data/latest_db/moalmanac_core__2025-09-04.csv\")\n",
    "standardized_to_raw_mapping['biomarker']=standardized_to_raw_mapping['biomarker'].apply(ast.literal_eval)\n",
    "standardized_to_raw_mapping['therapy']=standardized_to_raw_mapping['therapy'].apply(ast.literal_eval)\n",
    "print(standardized_to_raw_mapping.shape)\n",
    "standardized_to_raw_mapping.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "7d1a0201",
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_synthetic_query(db: dict) -> str:\n",
    "    \"\"\"\n",
    "    Create a synthetic query based on the database entry.\n",
    "    \"\"\"\n",
    "    if len(db['biomarker']) > 1:\n",
    "        biomarker_str = \", \".join(db['biomarker'])\n",
    "    else:\n",
    "        biomarker_str = db['biomarker'][0]\n",
    "    query_text=f\"if a patient with {db['modified_standardized_cancer']} cancer has {biomarker_str.lower()}, what therapy is recommended?\"\n",
    "    return query_text\n",
    "\n",
    "def create_synthetic_answer(db: dict) -> str:\n",
    "    \"\"\"\n",
    "    Create a synthetic answer based on the database entry.\n",
    "    \"\"\"\n",
    "    if len(db['biomarker']) > 1:\n",
    "        biomarker_str = \", \".join(db['biomarker'])\n",
    "    else:\n",
    "        biomarker_str = db['biomarker'][0]\n",
    "    if len(db['therapy']) > 1:\n",
    "        therapy_str = \" + \".join(db['therapy'])\n",
    "    else:\n",
    "        therapy_str = db['therapy'][0]\n",
    "    answer_text=f\"If a patient with {db['modified_standardized_cancer']} cancer has {biomarker_str.lower()}, one recommended therapy is {therapy_str.lower()}.\"\n",
    "    return answer_text\n",
    "\n",
    "synthetic_query_list = []\n",
    "synthetic_answer_list = []\n",
    "synthetic_query_therapy_pair_dict = {}\n",
    "for _, row in standardized_to_raw_mapping.iterrows():\n",
    "    #create synthetic query and answer and add to dataframe\n",
    "    query = create_synthetic_query(row)\n",
    "    answer = create_synthetic_answer(row)\n",
    "    standardized_to_raw_mapping.at[_, 'prompt'] = query\n",
    "    \n",
    "    #add more therapy context to answers (context db)\n",
    "    summary, stmt_row = flatten_statements(fda_statements[_])\n",
    "    if len(stmt_row['therapy_type']) > 1:\n",
    "        therapy_type = ' + '.join(stmt_row['therapy_type'])\n",
    "    else:\n",
    "        therapy_type = stmt_row['therapy_type'][0]\n",
    "    if len(stmt_row['therapy_strategy']) > 1:\n",
    "        therapy_strategy = ' + '.join(stmt_row['therapy_strategy'])\n",
    "    else:\n",
    "        therapy_strategy = stmt_row['therapy_strategy'][0]\n",
    "        \n",
    "    standardized_to_raw_mapping.at[_, 'answer'] = (\n",
    "        f\"{answer} therapy type: {therapy_type.lower()}. therapy strategy: {therapy_strategy.lower()}. indication: {stmt_row['indication'].lower()} approval url: {stmt_row['approval_url']}\"\n",
    "    )\n",
    "    \n",
    "    #create synthetic query and ground-truth mapping dict\n",
    "    row['therapy'] = [therapy.lower().strip() for therapy in row['therapy']]\n",
    "    if query in synthetic_query_therapy_pair_dict.keys():\n",
    "        synthetic_query_therapy_pair_dict[query].append(set(row['therapy']))\n",
    "    else:\n",
    "        synthetic_query_therapy_pair_dict[query] = [set(row['therapy'])]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "a7b5cb1e",
   "metadata": {},
   "outputs": [],
   "source": [
    "test_idx_list = split_ranges(standardized_to_raw_mapping.shape[0], 10, 50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "997934e6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0 if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has bard1 oncogenic variants, what therapy is recommended?\n",
      "1 if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?\n",
      "2 if a patient with metastatic non-small cell lung cancer cancer has pd-l1 >= 10% tiic, what therapy is recommended?\n",
      "3 if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?\n",
      "4 if a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr exon 20 (insertion), what therapy is recommended?\n",
      "5 if a patient with metastatic colorectal adenocarcinoma cancer has egfr positive, wild type kras, what therapy is recommended?\n",
      "6 if a patient with metastatic non-small cell lung cancer cancer has met exon 14 (deletion), what therapy is recommended?\n",
      "7 if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, pten deletion, what therapy is recommended?\n",
      "8 if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?\n",
      "9 if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten frameshift variants, pr positive, her2-negative, what therapy is recommended?\n",
      "10 if a patient with unresectable or metastatic melanoma cancer has braf p.v600k, what therapy is recommended?\n"
     ]
    }
   ],
   "source": [
    "for i, e in enumerate(standardized_to_raw_mapping.loc[test_idx_list].prompt):\n",
    "    print(i, e)\n",
    "    if i == 10:\n",
    "        break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "8f59fa8b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0 If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has bard1 oncogenic variants, one recommended therapy is prednisone + niraparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: akeega is a combination of niraparib, a poly (adp-ribose) polymerase (parp) inhibitor, and abiraterone acetate, a cyp17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved test for akeega. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\n",
      "1 If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\n",
      "2 If a patient with metastatic non-small cell lung cancer cancer has pd-l1 >= 10% tiic, one recommended therapy is atezolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated for the first-line treatment of adult patients with metastatic nsclc whose tumors have high pd-l1 expression (pd-l1 stained >= 50% of tumor cells [tc >= 50%] or pd-l1 stained tumor-infiltrating immune cells [ic] covering >= 10% of the tumor area [ic >= 10%] ), as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\n",
      "3 If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, one recommended therapy is asciminib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: scemblix is a kinase inhibitor indicated for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf\n",
      "4 If a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr exon 20 (insertion), one recommended therapy is amivantamab. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: rybrevant is a bispecific egf receptor-directed and met receptor-directed antibody indicated as a single agent for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 20 insertion mutations, as detected by an fda-approved test, whose disease has progressed on or after platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf\n",
      "5 If a patient with metastatic colorectal adenocarcinoma cancer has egfr positive, wild type kras, one recommended therapy is fluorouracil + irinotecan + cetuximab. therapy type: chemotherapy + chemotherapy + targeted therapy. therapy strategy: thymidylate synthase inhibition + topoisomerase i inhibition + egfr inhibition. indication: erbitux is an epidermal growth factor receptor (egfr) antagonist indicated for treatment of k-ras wild-type, egfr-expressing, metastatic colorectal cancer as determined by an fda-approved test in combination with folfiri for first-line treatment. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf\n",
      "6 If a patient with metastatic non-small cell lung cancer cancer has met exon 14 (deletion), one recommended therapy is capmatinib. therapy type: targeted therapy. therapy strategy: met inhibition. indication: tabrecta is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have a mutation that leads to mesenchymal-epithelial transition (met) exon 14 skipping as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf\n",
      "7 If a patient with locally advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, pten deletion, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\n",
      "8 If a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + gemcitabine + cisplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + antimetabolite + platinum-based chemotherapy. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\n",
      "9 If a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten frameshift variants, pr positive, her2-negative, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\n",
      "10 If a patient with unresectable or metastatic melanoma cancer has braf p.v600k, one recommended therapy is binimetinib + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda-approved test. braftovi is not indicated for treatment of patients with wild-type braf melanoma, wild-type braf crc, or wild-type braf nsclc. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf\n"
     ]
    }
   ],
   "source": [
    "for i, e in enumerate(standardized_to_raw_mapping.loc[test_idx_list].answer):\n",
    "    print(i, e)\n",
    "    if i == 10:\n",
    "        break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "989d7b3b",
   "metadata": {},
   "outputs": [],
   "source": [
    "save_object(synthetic_query_therapy_pair_dict, \"data/latest_db/synthetic_query_therapy_pair_dict.pkl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "d6abbb63",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "if a patient with early invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended? [{'tamoxifen', 'abemaciclib'}, {'abemaciclib', 'letrozole'}, {'anastrozole', 'goserelin', 'ribociclib'}, {'goserelin', 'letrozole', 'ribociclib'}, {'anastrozole', 'abemaciclib'}, {'abemaciclib', 'exemestane'}]\n"
     ]
    }
   ],
   "source": [
    "for k, v in synthetic_query_therapy_pair_dict.items():\n",
    "    print(k, v)\n",
    "    break"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "aa711ad8",
   "metadata": {},
   "source": [
    "### Save synthetic prompts and answers/context"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "1928b1a5",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(f\"data/latest_db/synthetic_prompts__{version}.json\", \"w\") as f:\n",
    "    json.dump(standardized_to_raw_mapping.prompt.to_list(), f)\n",
    "\n",
    "with open(f\"data/latest_db/synthetic_answers__{version}.json\", \"w\") as f:\n",
    "    json.dump(standardized_to_raw_mapping.answer.to_list(), f)\n",
    "    "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "442aad2d",
   "metadata": {},
   "source": [
    "### Save synthetic answers as context index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "c0aaa5bc",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "If a patient with early invasive breast carcinoma cancer has her2-negative, er positive, one recommended therapy is tamoxifen + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\n",
      "642\n"
     ]
    }
   ],
   "source": [
    "_CONTEXT = standardized_to_raw_mapping.answer.to_list()\n",
    "print(_CONTEXT[0])\n",
    "print(len(_CONTEXT))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "819c4f84",
   "metadata": {},
   "outputs": [],
   "source": [
    "def _cache_paths(output_dir: str, embed_name: str, name: str, version: str = \"v1\"):\n",
    "    os.makedirs(output_dir, exist_ok=True)\n",
    "    return (\n",
    "        f\"{output_dir}/{embed_name}_{name}__{version}.faiss\",\n",
    "        f\"{output_dir}/{embed_name}_{name}__{version}.json\",\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "8c8588cb",
   "metadata": {},
   "outputs": [],
   "source": [
    "load_dotenv()\n",
    "api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "_CLIENT = OpenAI(api_key=api_key)\n",
    "_MODEL_EMBED = \"text-embedding-3-small\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4266f7d8",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Always prefer cached index if present; only build once\n",
    "force_rebuild=False\n",
    "index_path, ctx_path =_cache_paths(\"data/latest_db/indexes\", _MODEL_EMBED, \"structured_context\", version=version)\n",
    "context_json_path=f\"data/latest_db/synthetic_answers__{version}.json\"\n",
    "\n",
    "if (not force_rebuild) and os.path.exists(index_path) and os.path.exists(ctx_path):\n",
    "    with open(ctx_path, \"r\") as f:\n",
    "        _CONTEXT = json.load(f)\n",
    "    _INDEX = faiss.read_index(index_path)\n",
    "else:\n",
    "    with open(context_json_path, \"r\") as f:\n",
    "        _CONTEXT = json.load(f)\n",
    "    _INDEX = get_context_db(_CONTEXT, _CLIENT, _MODEL_EMBED)\n",
    "    faiss.write_index(_INDEX, index_path)\n",
    "    with open(ctx_path, \"w\") as f:\n",
    "        json.dump(_CONTEXT, f)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c32020d0",
   "metadata": {},
   "source": [
    "## Create validation test dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "e1d9d651",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "statement_id",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "standardized_cancer",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "raw_cancer",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "modified_standardized_cancer",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "biomarker",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "therapy",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "prompt",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "answer",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "664f65d5-870b-4167-904a-2d520fe39811",
       "rows": [
        [
         "86",
         "87",
         "Colorectal Adenocarcinoma",
         "metastatic colorectal cancer",
         "metastatic colorectal adenocarcinoma",
         "['BRAF p.V600E']",
         "['Cetuximab', 'Encorafenib']",
         "if a patient with metastatic colorectal adenocarcinoma cancer has braf p.v600e, what therapy is recommended?",
         "If a patient with metastatic colorectal adenocarcinoma cancer has braf p.v600e, one recommended therapy is cetuximab + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + b-raf inhibition. indication: erbitux is an epidermal growth factor receptor (egfr) antagonist indicated for treatment of in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf"
        ],
        [
         "192",
         "193",
         "Acute Lymphoid Leukemia",
         "B-cell precursor acute lymphoblastic leukemia (ALL)",
         "b-cell precursor acute lymphoid leukemia",
         "['CD22 +']",
         "['Inotuzumab ozogamicin']",
         "if a patient with b-cell precursor acute lymphoid leukemia cancer has cd22 +, what therapy is recommended?",
         "If a patient with b-cell precursor acute lymphoid leukemia cancer has cd22 +, one recommended therapy is inotuzumab ozogamicin. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: besponsa is a cd22-directed antibody and cytotoxic drug conjugate indicated for the treatment of relapsed or refractory cd22-positive b-cell precursor acute lymphoblastic leukemia (all) in adult and pediatric patients 1 year and older. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf"
        ],
        [
         "479",
         "481",
         "Non-Small Cell Lung Cancer",
         "locally advanced or metastatic non-small cell lung cancer",
         "locally advanced or metastatic non-small cell lung cancer",
         "['KRAS p.G12C']",
         "['Sotorasib']",
         "if a patient with locally advanced or metastatic non-small cell lung cancer cancer has kras p.g12c, what therapy is recommended?",
         "If a patient with locally advanced or metastatic non-small cell lung cancer cancer has kras p.g12c, one recommended therapy is sotorasib. therapy type: targeted therapy. therapy strategy: ras inhibition. indication: lumakras is an inhibitor of the ras gtpase family indicated for the treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior systemic therapy. this indication is approved under accelerated approval based on overall response rate (orr) and duration of response (dor). continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s004lbl.pdf"
        ],
        [
         "616",
         "619",
         "Invasive Breast Carcinoma",
         "early breast cancer",
         "early invasive breast carcinoma",
         "['HER2-negative', 'ER positive']",
         "['Anastrozole', 'Abemaciclib']",
         "if a patient with early invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?",
         "If a patient with early invasive breast carcinoma cancer has her2-negative, er positive, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf"
        ],
        [
         "72",
         "73",
         "Invasive Breast Carcinoma",
         "locally advanced or metastatic breast cancer",
         "locally advanced or metastatic invasive breast carcinoma",
         "['PTEN splice site variants', 'HER2-negative', 'ER positive']",
         "['Fulvestrant', 'Capivasertib']",
         "if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten splice site variants, her2-negative, er positive, what therapy is recommended?",
         "If a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten splice site variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf"
        ],
        [
         "590",
         "593",
         "Colorectal Adenocarcinoma",
         "colorectal cancer",
         "colorectal adenocarcinoma",
         "['dMMR']",
         "['Nivolumab']",
         "if a patient with colorectal adenocarcinoma cancer has dmmr, what therapy is recommended?",
         "If a patient with colorectal adenocarcinoma cancer has dmmr, one recommended therapy is nivolumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf"
        ],
        [
         "231",
         "232",
         "Myelodysplastic Syndromes",
         "transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS)",
         "transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes",
         "['5q deletion']",
         "['Lenalidomide']",
         "if a patient with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes cancer has 5q deletion, what therapy is recommended?",
         "If a patient with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes cancer has 5q deletion, one recommended therapy is lenalidomide. therapy type: chemotherapy. therapy strategy: angiogenesis inhibition. indication: revlimid is a thalidomide analogue indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021880s067lbl.pdf"
        ],
        [
         "559",
         "561",
         "Astrocytoma",
         "astrocytoma or oligodendroglioma",
         "astrocytoma",
         "['IDH1 p.R132H']",
         "['Vorasidenib']",
         "if a patient with astrocytoma cancer has idh1 p.r132h, what therapy is recommended?",
         "If a patient with astrocytoma cancer has idh1 p.r132h, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf"
        ],
        [
         "399",
         "400",
         "Cholangiocarcinoma",
         "unresectable locally advanced or metastatic cholangiocarcinoma",
         "unresectable locally advanced or metastatic cholangiocarcinoma",
         "['FGFR2 rearrangements']",
         "['Pemigatinib']",
         "if a patient with unresectable locally advanced or metastatic cholangiocarcinoma cancer has fgfr2 rearrangements, what therapy is recommended?",
         "If a patient with unresectable locally advanced or metastatic cholangiocarcinoma cancer has fgfr2 rearrangements, one recommended therapy is pemigatinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: pemazyre is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as detected by an fda-approved test. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf"
        ],
        [
         "465",
         "467",
         "Peritoneal Serous Carcinoma",
         "epithelial ovarian, fallopian tube, or primary peritoneal cancer",
         "peritoneal serous carcinoma",
         "['BRCA2 oncogenic variants']",
         "['Rucaparib']",
         "if a patient with peritoneal serous carcinoma cancer has brca2 oncogenic variants, what therapy is recommended?",
         "If a patient with peritoneal serous carcinoma cancer has brca2 oncogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf"
        ],
        [
         "167",
         "168",
         "Non-Small Cell Lung Cancer",
         "metastatic non-small cell lung cancer",
         "metastatic non-small cell lung cancer",
         "['EGFR Exon 19 (Deletion)']",
         "['Gefitinib']",
         "if a patient with metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?",
         "If a patient with metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), one recommended therapy is gefitinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: iressa is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test. limitation of use: safety and efficacy of iressa have not been established in patients whose tumors have egfr mutations other than exon 19 deletions or exon 21 (l858r) substitution mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf"
        ],
        [
         "302",
         "303",
         "Invasive Breast Carcinoma",
         "high risk early breast cancer",
         "high risk early invasive breast carcinoma",
         "['HER2-negative', 'BRCA2 pathogenic variants']",
         "['Olaparib']",
         "if a patient with high risk early invasive breast carcinoma cancer has her2-negative, brca2 pathogenic variants, what therapy is recommended?",
         "If a patient with high risk early invasive breast carcinoma cancer has her2-negative, brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf"
        ],
        [
         "609",
         "612",
         "Non-Small Cell Lung Cancer",
         "metastatic non-small cell lung cancer",
         "metastatic non-small cell lung cancer",
         "['Wild type EGFR', 'Wild type ALK']",
         "['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Nab-paclitaxel']",
         "if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?",
         "If a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + carboplatin + durvalumab + nab-paclitaxel. therapy type: immunotherapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition + taxane-based chemotherapy. indication: imjudo is a cytotoxic t-lymphocyte-associated antigen 4 (ctla-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutation or anaplastic lymphoma kinase (alk) genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf"
        ],
        [
         "81",
         "82",
         "Non-Small Cell Lung Cancer",
         "non-small cell lung cancer",
         "non-small cell lung cancer",
         "['dMMR', 'Wild type EGFR', 'Wild type ALK', 'PD-L1 >= 50%']",
         "['Cemiplimab']",
         "if a patient with non-small cell lung cancer cancer has dmmr, wild type egfr, wild type alk, pd-l1 >= 50%, what therapy is recommended?",
         "If a patient with non-small cell lung cancer cancer has dmmr, wild type egfr, wild type alk, pd-l1 >= 50%, one recommended therapy is cemiplimab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: libtayo is a programmed death receptor-1 (pd-1) blocking antibody indicated as single agent for the first-line treatment of adult patients with nsclc whose tumors have high pd-l1 expression [tumor proportion score (tps) >= 50%] as determined by an fda-approved test, with no egfr, alk or ros1 aberrations, and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf"
        ],
        [
         "261",
         "262",
         "Non-Small Cell Lung Cancer",
         "non-small cell lung cancer",
         "non-small cell lung cancer",
         "['PD-L1 >= 1%']",
         "['Nivolumab', 'Ipilimumab']",
         "if a patient with non-small cell lung cancer cancer has pd-l1 >= 1%, what therapy is recommended?",
         "If a patient with non-small cell lung cancer cancer has pd-l1 >= 1%, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult patients with metastatic non-small cell lung cancer expressing pd-l1 (>= 1%) as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations, as first-line treatment in combination with ipilimumab. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf"
        ],
        [
         "525",
         "527",
         "Prostate Adenocarcinoma",
         "metastatic castration-resistant prostate cancer",
         "metastatic castration-resistant prostate adenocarcinoma",
         "['MLH1 pathogenic variants']",
         "['Enzalutamide', 'Talazoparib']",
         "if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has mlh1 pathogenic variants, what therapy is recommended?",
         "If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has mlh1 pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf"
        ],
        [
         "496",
         "498",
         "Non-Small Cell Lung Cancer",
         "unresectable or metastatic non-small cell lung cancer",
         "unresectable or metastatic non-small cell lung cancer",
         "['ERBB2 oncogenic variants']",
         "['Trastuzumab deruxtecan']",
         "if a patient with unresectable or metastatic non-small cell lung cancer cancer has erbb2 oncogenic variants, what therapy is recommended?",
         "If a patient with unresectable or metastatic non-small cell lung cancer cancer has erbb2 oncogenic variants, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (nsclc) whose tumors have activating her2 (erbb2) mutations, as detected by an fda-approved test, and who have received a prior systemic therapy. these indications are approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf"
        ],
        [
         "296",
         "297",
         "High-Grade Serous Fallopian Tube Cancer",
         "relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",
         "relapsed high-grade serous fallopian tube cancer",
         "['BRCA2 pathogenic variants']",
         "['Olaparib']",
         "if a patient with relapsed high-grade serous fallopian tube cancer cancer has brca2 pathogenic variants, what therapy is recommended?",
         "If a patient with relapsed high-grade serous fallopian tube cancer cancer has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf"
        ],
        [
         "69",
         "70",
         "Invasive Breast Carcinoma",
         "locally advanced or metastatic breast cancer",
         "locally advanced or metastatic invasive breast carcinoma",
         "['PTEN frameshift variants', 'HER2-negative', 'ER positive']",
         "['Fulvestrant', 'Capivasertib']",
         "if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten frameshift variants, her2-negative, er positive, what therapy is recommended?",
         "If a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten frameshift variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf"
        ],
        [
         "10",
         "10",
         "Invasive Breast Carcinoma",
         "advanced or metastatic breast cancer",
         "advanced or metastatic invasive breast carcinoma",
         "['PR positive', 'HER2-negative']",
         "['Fulvestrant', 'Abemaciclib']",
         "if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?",
         "If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is fulvestrant + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf"
        ],
        [
         "247",
         "248",
         "Non-Small Cell Lung Cancer",
         "locally advanced or metastatic non-small cell lung cancer",
         "locally advanced or metastatic non-small cell lung cancer",
         "['EGFR Exon 20 (Insertion)']",
         "['Mobocertinib']",
         "if a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr exon 20 (insertion), what therapy is recommended?",
         "If a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr exon 20 (insertion), one recommended therapy is mobocertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: exkivity is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 insertion mutations, as detected by an fda-approved test, whose disease has progressed on or after platinum-based chemotherapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s003lbl.pdf"
        ],
        [
         "63",
         "64",
         "Invasive Breast Carcinoma",
         "locally advanced or metastatic breast cancer",
         "locally advanced or metastatic invasive breast carcinoma",
         "['AKT1 amplification', 'HER2-negative', 'ER positive']",
         "['Fulvestrant', 'Capivasertib']",
         "if a patient with locally advanced or metastatic invasive breast carcinoma cancer has akt1 amplification, her2-negative, er positive, what therapy is recommended?",
         "If a patient with locally advanced or metastatic invasive breast carcinoma cancer has akt1 amplification, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf"
        ],
        [
         "457",
         "459",
         "Ovarian Epithelial Tumor",
         "epithelial ovarian, fallopian tube, or primary peritoneal cancer",
         "ovarian epithelial tumor",
         "['BRCA2 oncogenic variants']",
         "['Rucaparib']",
         "if a patient with ovarian epithelial tumor cancer has brca2 oncogenic variants, what therapy is recommended?",
         "If a patient with ovarian epithelial tumor cancer has brca2 oncogenic variants, one recommended therapy is rucaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf"
        ],
        [
         "54",
         "55",
         "Anaplastic Large Cell Lymphoma",
         "cutaneous analastplci large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF)",
         "cutaneous anaplastic large cell lymphoma",
         "['CD30 +']",
         "['Brentuximab vedotin']",
         "if a patient with cutaneous anaplastic large cell lymphoma cancer has cd30 +, what therapy is recommended?",
         "If a patient with cutaneous anaplastic large cell lymphoma cancer has cd30 +, one recommended therapy is brentuximab vedotin. therapy type: targeted therapy. therapy strategy: target cd30 antigens. indication: adcetris is a cd30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcalcl) or cd30-expressing mycosis fungoides (mf) who have received prior systemic therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf"
        ],
        [
         "527",
         "529",
         "Prostate Adenocarcinoma",
         "metastatic castration-resistant prostate cancer",
         "metastatic castration-resistant prostate adenocarcinoma",
         "['RAD51C pathogenic variants']",
         "['Enzalutamide', 'Talazoparib']",
         "if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad51c pathogenic variants, what therapy is recommended?",
         "If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad51c pathogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf"
        ],
        [
         "278",
         "279",
         "Ovarian Epithelial Tumor",
         "advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",
         "advanced ovarian epithelial tumor",
         "['HRD']",
         "['Olaparib', 'Bevacizumab']",
         "if a patient with advanced ovarian epithelial tumor cancer has hrd, what therapy is recommended?",
         "If a patient with advanced ovarian epithelial tumor cancer has hrd, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf"
        ],
        [
         "522",
         "524",
         "Prostate Adenocarcinoma",
         "metastatic castration-resistant prostate cancer",
         "metastatic castration-resistant prostate adenocarcinoma",
         "['MLH1 oncogenic variants']",
         "['Enzalutamide', 'Talazoparib']",
         "if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has mlh1 oncogenic variants, what therapy is recommended?",
         "If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has mlh1 oncogenic variants, one recommended therapy is enzalutamide + talazoparib. therapy type: hormone therapy + targeted therapy. therapy strategy: antiandrogen + parp inhibition. indication: talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf"
        ],
        [
         "101",
         "102",
         "Any solid tumor",
         "unresectable or metastatic solid tumors",
         "unresectable or metastatic any solid tumor",
         "['BRAF p.V600E']",
         "['Trametinib', 'Dabrafenib']",
         "if a patient with unresectable or metastatic any solid tumor cancer has braf p.v600e, what therapy is recommended?",
         "If a patient with unresectable or metastatic any solid tumor cancer has braf p.v600e, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: tafinlar is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. this indication is approved under accelerated approval based on overall response rate (orr) and duration of response (dor). continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf"
        ],
        [
         "118",
         "119",
         "Non-Small Cell Lung Cancer",
         "metastatic non-small cell lung cancer",
         "metastatic non-small cell lung cancer",
         "['Wild type EGFR', 'Wild type ALK']",
         "['Tremelimumab', 'Durvalumab', 'Pemetrexed', 'Cisplatin']",
         "if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?",
         "If a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + pemetrexed + cisplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf"
        ],
        [
         "31",
         "31",
         "APL with PML-RARA",
         "acute promyelocytic leukemia (APL)",
         "apl with pml-rara",
         "['PML::RARA']",
         "['Arsenic trioxide']",
         "if a patient with apl with pml-rara cancer has pml::rara, what therapy is recommended?",
         "If a patient with apl with pml-rara cancer has pml::rara, one recommended therapy is arsenic trioxide. therapy type: targeted therapy. therapy strategy: pml::rara inhibition. indication: trisenox is an arsenical indicated for induction of remission and consolidation in patients with apl who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterized by the presence of the t(15;17) translocation or pml/rar-alpha gene expression. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf"
        ],
        [
         "281",
         "282",
         "High-Grade Serous Fallopian Tube Cancer",
         "advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",
         "advanced high-grade serous fallopian tube cancer",
         "['BRCA2 oncogenic variants']",
         "['Olaparib', 'Bevacizumab']",
         "if a patient with advanced high-grade serous fallopian tube cancer cancer has brca2 oncogenic variants, what therapy is recommended?",
         "If a patient with advanced high-grade serous fallopian tube cancer cancer has brca2 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf"
        ],
        [
         "55",
         "56",
         "Non-Small Cell Lung Cancer",
         "metastatic non-small cell lung cancer",
         "metastatic non-small cell lung cancer",
         "['v::ALK']",
         "['Brigatinib']",
         "if a patient with metastatic non-small cell lung cancer cancer has v::alk, what therapy is recommended?",
         "If a patient with metastatic non-small cell lung cancer cancer has v::alk, one recommended therapy is brigatinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: alunbrig is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc) as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf"
        ],
        [
         "338",
         "339",
         "Prostate Adenocarcinoma",
         "metastatic castration-resistant prostate cancer",
         "metastatic castration-resistant prostate adenocarcinoma",
         "['BRCA2 oncogenic variants']",
         "['Prednisolone', 'Olaparib', 'Abiraterone acetate']",
         "if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 oncogenic variants, what therapy is recommended?",
         "If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 oncogenic variants, one recommended therapy is prednisolone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf"
        ],
        [
         "264",
         "265",
         "Ovarian Epithelial Tumor",
         "advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",
         "advanced ovarian epithelial tumor",
         "['BRCA2 oncogenic variants']",
         "['Olaparib']",
         "if a patient with advanced ovarian epithelial tumor cancer has brca2 oncogenic variants, what therapy is recommended?",
         "If a patient with advanced ovarian epithelial tumor cancer has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf"
        ],
        [
         "543",
         "545",
         "Non-Small Cell Lung Cancer",
         "non-small cell lung cancer",
         "non-small cell lung cancer",
         "['EGFR Exon 19 (Deletion)']",
         "['Carboplatin', 'Amivantamab', 'Pemetrexed']",
         "if a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?",
         "If a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), one recommended therapy is carboplatin + amivantamab + pemetrexed. therapy type: chemotherapy + targeted therapy + chemotherapy. therapy strategy: platinum-based chemotherapy + egfr inhibition + antifolate. indication: rybrevant is a bispecific egf receptor-directed and met receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 19 deletions or exon 21 l858r substitution mutations, whose disease has progressed on or after treatment with an egfr tyrosine kinase inhibitor. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf"
        ],
        [
         "176",
         "177",
         "Acute Lymphoid Leukemia",
         "relapsed or refractory acute myeloid leukemia",
         "relapsed or refractory acute lymphoid leukemia",
         "['FLT3 p.D835N']",
         "['Gilteritinib']",
         "if a patient with relapsed or refractory acute lymphoid leukemia cancer has flt3 p.d835n, what therapy is recommended?",
         "If a patient with relapsed or refractory acute lymphoid leukemia cancer has flt3 p.d835n, one recommended therapy is gilteritinib. therapy type: targeted therapy. therapy strategy: flt3 inhibition. indication: xospata is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf"
        ],
        [
         "108",
         "109",
         "Chronic Myeloid Leukemia, BCR-ABL1+",
         "chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML",
         "chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myeloid leukemia, bcr-abl1+",
         "['BCR::ABL1']",
         "['Dasatinib']",
         "if a patient with chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, what therapy is recommended?",
         "If a patient with chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is a kinase inhibitor indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase ph+ cml with resistance or intolerance to prior therapy including imatinib. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf"
        ],
        [
         "424",
         "425",
         "Invasive Breast Carcinoma",
         "early stage breast cancer",
         "early stage invasive breast carcinoma",
         "['HER2-positive']",
         "['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']",
         "if a patient with early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?",
         "If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf"
        ],
        [
         "208",
         "209",
         "Acute Myeloid Leukemia",
         "acute myeloid leukemia",
         "acute myeloid leukemia",
         "['IDH1 p.R132S']",
         "['Ivosidenib', 'Azacitidine']",
         "if a patient with acute myeloid leukemia cancer has idh1 p.r132s, what therapy is recommended?",
         "If a patient with acute myeloid leukemia cancer has idh1 p.r132s, one recommended therapy is ivosidenib + azacitidine. therapy type: targeted therapy + chemotherapy. therapy strategy: idh1 inhibition + hypomethylating agent chemotherapy. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf"
        ],
        [
         "110",
         "111",
         "Chronic Myelogenous Leukemia",
         "philadelphia chromosome-positive CML",
         "philadelphia chromosome-positive chronic myelogenous leukemia",
         "['BCR::ABL1']",
         "['Dasatinib']",
         "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?",
         "If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with ph+ cml in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf"
        ],
        [
         "163",
         "164",
         "Invasive Breast Carcinoma",
         "advanced or metastatic breast cancer",
         "advanced or metastatic invasive breast carcinoma",
         "['HER2-negative', 'ER positive']",
         "['Fulvestrant', 'Abemaciclib']",
         "if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?",
         "If a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, one recommended therapy is fulvestrant + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is an estrogen receptor antagonist indicated for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf"
        ],
        [
         "284",
         "285",
         "Peritoneal Serous Carcinoma",
         "advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",
         "advanced peritoneal serous carcinoma",
         "['BRCA1 oncogenic variants']",
         "['Olaparib', 'Bevacizumab']",
         "if a patient with advanced peritoneal serous carcinoma cancer has brca1 oncogenic variants, what therapy is recommended?",
         "If a patient with advanced peritoneal serous carcinoma cancer has brca1 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either a deleterious or suspected deleterious brca mutation, and/or genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf"
        ],
        [
         "109",
         "110",
         "Acute Lymphoid Leukemia",
         "philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)",
         "philadelphia chromosome-positive acute lymphoid leukemia",
         "['BCR::ABL1']",
         "['Dasatinib']",
         "if a patient with philadelphia chromosome-positive acute lymphoid leukemia cancer has bcr::abl1, what therapy is recommended?",
         "If a patient with philadelphia chromosome-positive acute lymphoid leukemia cancer has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is a kinase inhibitor indicated for the treatment of adults with philadelphia chromosome-positive acute lymphoblastic leukemia (ph+ all) with resistance or intolerance to prior therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf"
        ],
        [
         "76",
         "77",
         "Invasive Breast Carcinoma",
         "locally advanced or metastatic breast cancer",
         "locally advanced or metastatic invasive breast carcinoma",
         "['PR positive', 'HER2-negative', 'PTEN deletion']",
         "['Fulvestrant', 'Capivasertib']",
         "if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, pten deletion, what therapy is recommended?",
         "If a patient with locally advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, pten deletion, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf"
        ],
        [
         "501",
         "503",
         "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease",
         "Erdheim-Chester Disease",
         "non-langerhans cell histiocytosis/erdheim-chester disease",
         "['BRAF p.V600E']",
         "['Vemurafenib']",
         "if a patient with non-langerhans cell histiocytosis/erdheim-chester disease cancer has braf p.v600e, what therapy is recommended?",
         "If a patient with non-langerhans cell histiocytosis/erdheim-chester disease cancer has braf p.v600e, one recommended therapy is vemurafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf"
        ],
        [
         "2",
         "2",
         "Invasive Breast Carcinoma",
         "early breast cancer",
         "early invasive breast carcinoma",
         "['PR positive', 'HER2-negative', 'ER positive']",
         "['Tamoxifen', 'Abemaciclib']",
         "if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?",
         "If a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, er positive, one recommended therapy is tamoxifen + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf"
        ],
        [
         "576",
         "578",
         "Oligodendroglioma",
         "astrocytoma or oligodendroglioma",
         "oligodendroglioma",
         "['IDH2 p.R172W']",
         "['Vorasidenib']",
         "if a patient with oligodendroglioma cancer has idh2 p.r172w, what therapy is recommended?",
         "If a patient with oligodendroglioma cancer has idh2 p.r172w, one recommended therapy is vorasidenib. therapy type: targeted therapy. therapy strategy: idh1/2 inhibition. indication: voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf"
        ],
        [
         "268",
         "269",
         "High-Grade Serous Fallopian Tube Cancer",
         "advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",
         "advanced high-grade serous fallopian tube cancer",
         "['BRCA2 oncogenic variants']",
         "['Olaparib']",
         "if a patient with advanced high-grade serous fallopian tube cancer cancer has brca2 oncogenic variants, what therapy is recommended?",
         "If a patient with advanced high-grade serous fallopian tube cancer cancer has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf"
        ],
        [
         "357",
         "358",
         "Non-Small Cell Lung Cancer",
         "metastatic non-small cell lung cancer",
         "metastatic non-small cell lung cancer",
         "['EGFR p.T790M']",
         "['Osimertinib']",
         "if a patient with metastatic non-small cell lung cancer cancer has egfr p.t790m, what therapy is recommended?",
         "If a patient with metastatic non-small cell lung cancer cancer has egfr p.t790m, one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso is a kinase inhibitor indicated for the treatment of adult patients with metastatic egfr t790m mutation-positive nsclc, as detected by an fda-approved test, whose disease has progressed on or after egfr tki therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf"
        ],
        [
         "260",
         "261",
         "Non-Small Cell Lung Cancer",
         "non-small cell lung cancer",
         "non-small cell lung cancer",
         "['Wild type EGFR', 'Wild type ALK']",
         "['Carboplatin', 'Paclitaxel', 'Nivolumab']",
         "if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?",
         "If a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + paclitaxel + nivolumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + pd-1/pd-l1 inhibition. indication: opdivo is a programmed death receptor-1 (pd-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known egfr mutations or alk rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent opdivo as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf"
        ]
       ],
       "shape": {
        "columns": 8,
        "rows": 64
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>statement_id</th>\n",
       "      <th>standardized_cancer</th>\n",
       "      <th>raw_cancer</th>\n",
       "      <th>modified_standardized_cancer</th>\n",
       "      <th>biomarker</th>\n",
       "      <th>therapy</th>\n",
       "      <th>prompt</th>\n",
       "      <th>answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>87</td>\n",
       "      <td>Colorectal Adenocarcinoma</td>\n",
       "      <td>metastatic colorectal cancer</td>\n",
       "      <td>metastatic colorectal adenocarcinoma</td>\n",
       "      <td>[BRAF p.V600E]</td>\n",
       "      <td>[Cetuximab, Encorafenib]</td>\n",
       "      <td>if a patient with metastatic colorectal adenoc...</td>\n",
       "      <td>If a patient with metastatic colorectal adenoc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>192</th>\n",
       "      <td>193</td>\n",
       "      <td>Acute Lymphoid Leukemia</td>\n",
       "      <td>B-cell precursor acute lymphoblastic leukemia ...</td>\n",
       "      <td>b-cell precursor acute lymphoid leukemia</td>\n",
       "      <td>[CD22 +]</td>\n",
       "      <td>[Inotuzumab ozogamicin]</td>\n",
       "      <td>if a patient with b-cell precursor acute lymph...</td>\n",
       "      <td>If a patient with b-cell precursor acute lymph...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>479</th>\n",
       "      <td>481</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>locally advanced or metastatic non-small cell ...</td>\n",
       "      <td>locally advanced or metastatic non-small cell ...</td>\n",
       "      <td>[KRAS p.G12C]</td>\n",
       "      <td>[Sotorasib]</td>\n",
       "      <td>if a patient with locally advanced or metastat...</td>\n",
       "      <td>If a patient with locally advanced or metastat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>616</th>\n",
       "      <td>619</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>early breast cancer</td>\n",
       "      <td>early invasive breast carcinoma</td>\n",
       "      <td>[HER2-negative, ER positive]</td>\n",
       "      <td>[Anastrozole, Abemaciclib]</td>\n",
       "      <td>if a patient with early invasive breast carcin...</td>\n",
       "      <td>If a patient with early invasive breast carcin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>73</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>locally advanced or metastatic breast cancer</td>\n",
       "      <td>locally advanced or metastatic invasive breast...</td>\n",
       "      <td>[PTEN splice site variants, HER2-negative, ER ...</td>\n",
       "      <td>[Fulvestrant, Capivasertib]</td>\n",
       "      <td>if a patient with locally advanced or metastat...</td>\n",
       "      <td>If a patient with locally advanced or metastat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>165</th>\n",
       "      <td>166</td>\n",
       "      <td>Invasive Breast Carcinoma</td>\n",
       "      <td>advanced or metastatic breast cancer</td>\n",
       "      <td>advanced or metastatic invasive breast carcinoma</td>\n",
       "      <td>[PR positive, HER2-negative, ER positive]</td>\n",
       "      <td>[Fulvestrant, Abemaciclib]</td>\n",
       "      <td>if a patient with advanced or metastatic invas...</td>\n",
       "      <td>If a patient with advanced or metastatic invas...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>79</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>metastatic non-small cell lung cancer</td>\n",
       "      <td>metastatic non-small cell lung cancer</td>\n",
       "      <td>[MET Exon 14 (Splice Site)]</td>\n",
       "      <td>[Capmatinib]</td>\n",
       "      <td>if a patient with metastatic non-small cell lu...</td>\n",
       "      <td>If a patient with metastatic non-small cell lu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>181</th>\n",
       "      <td>182</td>\n",
       "      <td>Chronic Myelogenous Leukemia</td>\n",
       "      <td>philadelphia chromosome-positive chronic myelo...</td>\n",
       "      <td>philadelphia chromosome-positive chronic myelo...</td>\n",
       "      <td>[BCR::ABL1]</td>\n",
       "      <td>[Imatinib]</td>\n",
       "      <td>if a patient with philadelphia chromosome-posi...</td>\n",
       "      <td>If a patient with philadelphia chromosome-posi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>587</th>\n",
       "      <td>589</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>non-small cell lung cancer</td>\n",
       "      <td>non-small cell lung cancer</td>\n",
       "      <td>[Wild type EGFR, Wild type ALK]</td>\n",
       "      <td>[Carboplatin, Paclitaxel, Nivolumab, Ipilimumab]</td>\n",
       "      <td>if a patient with non-small cell lung cancer c...</td>\n",
       "      <td>If a patient with non-small cell lung cancer c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>220</th>\n",
       "      <td>221</td>\n",
       "      <td>Cholangiocarcinoma</td>\n",
       "      <td>locally advanced or metastatic cholangiocarcinoma</td>\n",
       "      <td>locally advanced or metastatic cholangiocarcinoma</td>\n",
       "      <td>[IDH1 p.R132G]</td>\n",
       "      <td>[Ivosidenib]</td>\n",
       "      <td>if a patient with locally advanced or metastat...</td>\n",
       "      <td>If a patient with locally advanced or metastat...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>64 rows  8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     statement_id           standardized_cancer  \\\n",
       "86             87     Colorectal Adenocarcinoma   \n",
       "192           193       Acute Lymphoid Leukemia   \n",
       "479           481    Non-Small Cell Lung Cancer   \n",
       "616           619     Invasive Breast Carcinoma   \n",
       "72             73     Invasive Breast Carcinoma   \n",
       "..            ...                           ...   \n",
       "165           166     Invasive Breast Carcinoma   \n",
       "78             79    Non-Small Cell Lung Cancer   \n",
       "181           182  Chronic Myelogenous Leukemia   \n",
       "587           589    Non-Small Cell Lung Cancer   \n",
       "220           221            Cholangiocarcinoma   \n",
       "\n",
       "                                            raw_cancer  \\\n",
       "86                        metastatic colorectal cancer   \n",
       "192  B-cell precursor acute lymphoblastic leukemia ...   \n",
       "479  locally advanced or metastatic non-small cell ...   \n",
       "616                                early breast cancer   \n",
       "72        locally advanced or metastatic breast cancer   \n",
       "..                                                 ...   \n",
       "165               advanced or metastatic breast cancer   \n",
       "78               metastatic non-small cell lung cancer   \n",
       "181  philadelphia chromosome-positive chronic myelo...   \n",
       "587                         non-small cell lung cancer   \n",
       "220  locally advanced or metastatic cholangiocarcinoma   \n",
       "\n",
       "                          modified_standardized_cancer  \\\n",
       "86                metastatic colorectal adenocarcinoma   \n",
       "192           b-cell precursor acute lymphoid leukemia   \n",
       "479  locally advanced or metastatic non-small cell ...   \n",
       "616                    early invasive breast carcinoma   \n",
       "72   locally advanced or metastatic invasive breast...   \n",
       "..                                                 ...   \n",
       "165   advanced or metastatic invasive breast carcinoma   \n",
       "78               metastatic non-small cell lung cancer   \n",
       "181  philadelphia chromosome-positive chronic myelo...   \n",
       "587                         non-small cell lung cancer   \n",
       "220  locally advanced or metastatic cholangiocarcinoma   \n",
       "\n",
       "                                             biomarker  \\\n",
       "86                                      [BRAF p.V600E]   \n",
       "192                                           [CD22 +]   \n",
       "479                                      [KRAS p.G12C]   \n",
       "616                       [HER2-negative, ER positive]   \n",
       "72   [PTEN splice site variants, HER2-negative, ER ...   \n",
       "..                                                 ...   \n",
       "165          [PR positive, HER2-negative, ER positive]   \n",
       "78                         [MET Exon 14 (Splice Site)]   \n",
       "181                                        [BCR::ABL1]   \n",
       "587                    [Wild type EGFR, Wild type ALK]   \n",
       "220                                     [IDH1 p.R132G]   \n",
       "\n",
       "                                              therapy  \\\n",
       "86                           [Cetuximab, Encorafenib]   \n",
       "192                           [Inotuzumab ozogamicin]   \n",
       "479                                       [Sotorasib]   \n",
       "616                        [Anastrozole, Abemaciclib]   \n",
       "72                        [Fulvestrant, Capivasertib]   \n",
       "..                                                ...   \n",
       "165                        [Fulvestrant, Abemaciclib]   \n",
       "78                                       [Capmatinib]   \n",
       "181                                        [Imatinib]   \n",
       "587  [Carboplatin, Paclitaxel, Nivolumab, Ipilimumab]   \n",
       "220                                      [Ivosidenib]   \n",
       "\n",
       "                                                prompt  \\\n",
       "86   if a patient with metastatic colorectal adenoc...   \n",
       "192  if a patient with b-cell precursor acute lymph...   \n",
       "479  if a patient with locally advanced or metastat...   \n",
       "616  if a patient with early invasive breast carcin...   \n",
       "72   if a patient with locally advanced or metastat...   \n",
       "..                                                 ...   \n",
       "165  if a patient with advanced or metastatic invas...   \n",
       "78   if a patient with metastatic non-small cell lu...   \n",
       "181  if a patient with philadelphia chromosome-posi...   \n",
       "587  if a patient with non-small cell lung cancer c...   \n",
       "220  if a patient with locally advanced or metastat...   \n",
       "\n",
       "                                                answer  \n",
       "86   If a patient with metastatic colorectal adenoc...  \n",
       "192  If a patient with b-cell precursor acute lymph...  \n",
       "479  If a patient with locally advanced or metastat...  \n",
       "616  If a patient with early invasive breast carcin...  \n",
       "72   If a patient with locally advanced or metastat...  \n",
       "..                                                 ...  \n",
       "165  If a patient with advanced or metastatic invas...  \n",
       "78   If a patient with metastatic non-small cell lu...  \n",
       "181  If a patient with philadelphia chromosome-posi...  \n",
       "587  If a patient with non-small cell lung cancer c...  \n",
       "220  If a patient with locally advanced or metastat...  \n",
       "\n",
       "[64 rows x 8 columns]"
      ]
     },
     "execution_count": 59,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "standardized_to_raw_mapping_subset=standardized_to_raw_mapping.sample(frac=.1, random_state=42)\n",
    "standardized_to_raw_mapping_subset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "8b63046e",
   "metadata": {},
   "outputs": [],
   "source": [
    "standardized_to_raw_mapping_subset.to_csv(\"data/latest_db/moalmanac_small_testing_dataset.csv\", index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6dc743b1",
   "metadata": {},
   "source": [
    "## Number of tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a25556b6",
   "metadata": {},
   "outputs": [],
   "source": [
    "standardized_to_raw_mapping_subset = pd.read_csv(\"data/latest_db/moalmanac_prompts_subset.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "3c553be8",
   "metadata": {},
   "outputs": [],
   "source": [
    "import tiktoken\n",
    "encoding = tiktoken.encoding_for_model(\"gpt-4o\")  # or \"gpt-4\", \"gpt-3.5-turbo\", etc."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "0d57c501",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# chunks: 64\n",
      "Min: 18\n",
      "Max: 44\n",
      "Mean: 25.9375\n",
      "Median: 25.5\n"
     ]
    }
   ],
   "source": [
    "query_size=[len(encoding.encode(prompt)) for prompt in standardized_to_raw_mapping_subset.prompt]\n",
    "print(\"# chunks: \"+str(len(query_size)))\n",
    "print(\"Min: \"+str(np.min(query_size)))\n",
    "print(\"Max: \"+str(np.max(query_size)))\n",
    "print(\"Mean: \"+str(np.mean(query_size)))\n",
    "print(\"Median: \"+str(np.median(query_size)))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "16163a71",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1660"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "np.sum(query_size)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "1efca32c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# chunks: 64\n",
      "Min: 25\n",
      "Max: 49\n",
      "Mean: 35.1875\n",
      "Median: 33.0\n"
     ]
    }
   ],
   "source": [
    "query_size=[len(encoding.encode(prompt)) for prompt in standardized_to_raw_mapping_subset.answer]\n",
    "print(\"# chunks: \"+str(len(query_size)))\n",
    "print(\"Min: \"+str(np.min(query_size)))\n",
    "print(\"Max: \"+str(np.max(query_size)))\n",
    "print(\"Mean: \"+str(np.mean(query_size)))\n",
    "print(\"Median: \"+str(np.median(query_size)))\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "800c7f89",
   "metadata": {},
   "source": [
    "## Quick evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "4c7b48da",
   "metadata": {},
   "outputs": [],
   "source": [
    "#load test subset\n",
    "standardized_to_raw_mapping_subset = pd.read_csv(\"data/latest_db/moalmanac_small_testing_dataset.csv\")\n",
    "\n",
    "#load synthetic query and ground-truth answer pair\n",
    "synthetic_query_therapy_pair_dict=load_object(\"data/latest_db/synthetic_query_therapy_pair_dict.pkl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "68d5bc67",
   "metadata": {},
   "outputs": [],
   "source": [
    "# output_res = load_object(f\"{root_dir}/output/RAG_res_gpt4o/structured_latest_db_prompts/RAGbatchstra0n1temp0.0_res_dict.pkl\")\n",
    "output_res = load_object(f\"output/RAG_res_gpt4o/structured_latest_db_prompts_humantextctxv1/RAGbatchstra0n1temp0.0_res_dict.pkl\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "97c7055f",
   "metadata": {},
   "source": [
    "### Check batch job status"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "f309947e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Batch(id='batch_68c05731f23c8190a037c9d60c6b07dc', completion_window='24h', created_at=1757435697, endpoint='/v1/chat/completions', input_file_id='file-VJaW3p7b1vTSERTSLueXCE', object='batch', status='failed', cancelled_at=None, cancelling_at=None, completed_at=None, error_file_id=None, errors=Errors(data=[BatchError(code='token_limit_exceeded', line=None, message='Enqueued token limit reached for gpt-4o-2024-05-13 in organization org-21HgjHxT7v4qV6YYhGGApRRN. Limit: 90,000 enqueued tokens. Please try again once some in_progress batches have been completed.', param=None)], object='list'), expired_at=None, expires_at=1757522097, failed_at=1757435700, finalizing_at=None, in_progress_at=None, metadata=None, output_file_id=None, request_counts=BatchRequestCounts(completed=0, failed=0, total=0), usage={'input_tokens': 0, 'output_tokens': 0, 'total_tokens': 0, 'input_tokens_details': {'cached_tokens': 0}, 'output_tokens_details': {'reasoning_tokens': 0}})\n"
     ]
    }
   ],
   "source": [
    "from openai import OpenAI\n",
    "\n",
    "load_dotenv()\n",
    "api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "_CLIENT = OpenAI(api_key=api_key)\n",
    "batch = _CLIENT.batches.retrieve(\"batch_68c05731f23c8190a037c9d60c6b07dc\")\n",
    "print(batch)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "303bc216",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "batch_68c06d02ffc08190a4050d97558d64a0 completed\n",
      "batch_68bf621f8a28819085f7bf43a9986802 completed\n"
     ]
    }
   ],
   "source": [
    "jobs = _CLIENT.batches.list()\n",
    "for j in jobs.data:\n",
    "    print(j.id, j.status)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "515b4c04",
   "metadata": {},
   "source": [
    "Calculate evaluation metrics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cc07455c",
   "metadata": {},
   "outputs": [],
   "source": [
    "from utils.evaluation import calc_eval_metrics\n",
    "\n",
    "output_eval = calc_eval_metrics(output_res['full output'][0], standardized_to_raw_mapping_subset.reset_index(drop=True)['prompt'], synthetic_query_therapy_pair_dict)\n",
    "output_eval"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5a4534bb",
   "metadata": {},
   "source": [
    "Review exact match failed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d4e583fe",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index([3, 19, 32, 34, 37, 38, 39, 40, 45, 49, 50, 55, 57, 58, 59, 61, 62], dtype='int64')"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "exact_failed_ind = standardized_to_raw_mapping_subset.reset_index(drop=True)[~np.array(output_eval['exact_match_acc'])].index\n",
    "print(exact_failed_ind)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "9651f268",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "if a patient with early invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?\n",
      "[{'abemaciclib', 'tamoxifen'}, {'abemaciclib', 'letrozole'}, {'ribociclib', 'goserelin', 'anastrozole'}, {'ribociclib', 'goserelin', 'letrozole'}, {'abemaciclib', 'anastrozole'}, {'exemestane', 'abemaciclib'}]\n",
      "6\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is a her2/neu receptor antagonist indicated for the treatment of her2 -overexpressing breast cancer. select patients for therapy based on an fda-approved companion diagnostic for herceptin. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf', 'If a patient with early-stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is neratinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: nerlynx is a kinase inhibitor indicated as a single agent, for the extended adjuvant treatment of adult patients with early-stage her2-positive breast cancer, to follow adjuvant trastuzumab based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early invasive breast carcinoma cancer has her2-negative, er positive, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with metastatic invasive breast carcinoma cancer has her2-positive, one recommended therapy is eribulin + margetuximab. therapy type: chemotherapy + hormone therapy. therapy strategy: tubulin polymerization inhibition + her2 inhibition. indication: margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + doxorubicin + fluorouracil + docetaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + carboplatin + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + taxane-based chemotherapy + her2 inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with early invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Early Invasive Breast Carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"HER2-negative, ER-positive\",\n",
      "        \"Drug Name\": \"Abemaciclib + Letrozole\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"HER2-negative, ER-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?\n",
      "[{'abemaciclib', 'anastrozole'}, {'abemaciclib', 'letrozole'}, {'abemaciclib', 'fulvestrant'}, {'abemaciclib'}, {'ribociclib', 'fulvestrant'}, {'fulvestrant', 'palbociclib'}, {'abemaciclib', 'fulvestrant'}, {'palbociclib', 'letrozole'}, {'fulvestrant', 'palbociclib'}, {'ribociclib', 'anastrozole'}, {'ribociclib', 'letrozole'}, {'ribociclib', 'fulvestrant'}]\n",
      "12\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is a her2/neu receptor antagonist indicated for the treatment of her2 -overexpressing breast cancer. select patients for therapy based on an fda-approved companion diagnostic for herceptin. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf', 'If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is abemaciclib. therapy type: targeted therapy. therapy strategy: cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + carboplatin + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + taxane-based chemotherapy + her2 inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + doxorubicin + fluorouracil + docetaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with metastatic invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and docetaxel for treatment of patients with her2-positive metastatic breast cancer (mbc) who have not received prior anti-her2 therapy or chemotherapy for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Invasive Breast Carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n",
      "        \"Drug Name\": \"Abemaciclib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Disease progression following endocrine therapy and prior chemotherapy in the metastatic setting\",\n",
      "        \"Genomic Features\": \"PR positive, HER2-negative\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Invasive Breast Carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n",
      "        \"Drug Name\": \"Abemaciclib + Letrozole\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Initial endocrine-based therapy\",\n",
      "        \"Genomic Features\": \"PR positive, HER2-negative\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 oncogenic variants, what therapy is recommended?\n",
      "[{'olaparib'}, {'abiraterone acetate', 'olaparib', 'prednisolone'}, {'abiraterone acetate', 'olaparib', 'prednisone'}, {'rucaparib'}, {'enzalutamide', 'talazoparib'}]\n",
      "5\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 pathogenic variants, one recommended therapy is prednisone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 oncogenic variants, one recommended therapy is prednisone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 pathogenic variants, one recommended therapy is prednisolone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 oncogenic variants, one recommended therapy is prednisolone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 oncogenic variants, one recommended therapy is prednisone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 pathogenic variants, one recommended therapy is prednisone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 oncogenic variants, one recommended therapy is prednisolone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 pathogenic variants, one recommended therapy is prednisolone + olaparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'If a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 oncogenic variants, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Prostate Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Prednisone + Olaparib + Abiraterone Acetate\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRCA2 Oncogenic Variants\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Prostate Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Prednisolone + Olaparib + Abiraterone Acetate\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRCA2 Oncogenic Variants\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Prostate Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n",
      "        \"Genomic Features\": \"BRCA2 Oncogenic Variants\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?\n",
      "[{'osimertinib'}, {'osimertinib'}, {'amivantamab', 'lazertinib'}, {'amivantamab', 'pemetrexed', 'carboplatin'}, {'datopotamab deruxtecan'}]\n",
      "5\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), one recommended therapy is erlotinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tarceva is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. safety and efficacy of tarceva have not been established in patients with nsclc whose tumors have other egfr mutations. tarceva is not recommended for use in combination with platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf', 'If a patient with metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), one recommended therapy is gefitinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: iressa is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test. limitation of use: safety and efficacy of iressa have not been established in patients whose tumors have egfr mutations other than exon 19 deletions or exon 21 (l858r) substitution mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf', 'If a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso is a kinase inhibitor indicated for the treatment of adult patients with locally advanced, unresectable (stage iii) nsclc whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have egfr exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'If a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso is a kinase inhibitor indicated for adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'If a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), one recommended therapy is amivantamab + lazertinib. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + egfr inhibition. indication: lazcluze is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r substitution mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf', 'If a patient with metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso is a kinase inhibitor indicated for the first-line treatment of adult patients with metastatic nsclc whose tumors have egfr exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'If a patient with metastatic non-small cell lung cancer cancer has egfr p.l858r, one recommended therapy is erlotinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tarceva is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. safety and efficacy of tarceva have not been established in patients with nsclc whose tumors have other egfr mutations. tarceva is not recommended for use in combination with platinum-based chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf', 'If a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), one recommended therapy is carboplatin + amivantamab + pemetrexed. therapy type: chemotherapy + targeted therapy + chemotherapy. therapy strategy: platinum-based chemotherapy + egfr inhibition + antifolate. indication: rybrevant is a bispecific egf receptor-directed and met receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 19 deletions or exon 21 l858r substitution mutations, whose disease has progressed on or after treatment with an egfr tyrosine kinase inhibitor. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf', 'If a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), one recommended therapy is amivantamab + lazertinib. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + egfr inhibition. indication: rybrevant is a bispecific egf receptor-directed and met receptor-directed antibody indicated in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 19 deletions or exon 21 l858r substitution mutations, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf', 'If a patient with metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), one recommended therapy is erlotinib + ramucirumab. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + vegf/vegfr inhibition. indication: cyramza is a human vascular endothelial growth factor receptor 2 (vegfr2) antagonist indicated in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) mutations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Erlotinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"First-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen\",\n",
      "        \"Genomic Features\": \"EGFR exon 19 deletions\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Gefitinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"First-line treatment\",\n",
      "        \"Genomic Features\": \"EGFR exon 19 deletions\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Locally advanced, unresectable (Stage III)\",\n",
      "        \"Drug Name\": \"Osimertinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy\",\n",
      "        \"Genomic Features\": \"EGFR exon 19 deletions\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 4\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Adjuvant therapy after tumor resection\",\n",
      "        \"Drug Name\": \"Osimertinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "        \"Genomic Features\": \"EGFR exon 19 deletions\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 5\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n",
      "        \"Drug Name\": \"Amivantamab + Lazertinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"First-line treatment\",\n",
      "        \"Genomic Features\": \"EGFR exon 19 deletions\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf\"\n",
      "    },\n",
      "    \"Treatment 6\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Osimertinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"First-line treatment\",\n",
      "        \"Genomic Features\": \"EGFR exon 19 deletions\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 7\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n",
      "        \"Drug Name\": \"Amivantamab + Lazertinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"First-line treatment\",\n",
      "        \"Genomic Features\": \"EGFR exon 19 deletions\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 8\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n",
      "        \"Drug Name\": \"Carboplatin + Amivantamab + Pemetrexed\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor\",\n",
      "        \"Genomic Features\": \"EGFR exon 19 deletions\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 9\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Erlotinib + Ramucirumab\",\n",
      "        \"Prior Treatment or Resistance Status\": \"First-line treatment\",\n",
      "        \"Genomic Features\": \"EGFR exon 19 deletions\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?\n",
      "[{'epirubicin', 'trastuzumab', 'fluorouracil', 'pertuzumab', 'cyclophosphamide', 'paclitaxel'}, {'doxorubicin', 'docetaxel', 'trastuzumab', 'pertuzumab', 'cyclophosphamide', 'fluorouracil'}, {'doxorubicin', 'trastuzumab', 'fluorouracil', 'pertuzumab', 'cyclophosphamide', 'paclitaxel'}, {'docetaxel', 'epirubicin', 'trastuzumab', 'pertuzumab', 'cyclophosphamide'}, {'epirubicin', 'trastuzumab', 'pertuzumab', 'cyclophosphamide', 'paclitaxel'}, {'doxorubicin', 'docetaxel', 'trastuzumab', 'pertuzumab', 'cyclophosphamide'}, {'trastuzumab', 'pertuzumab', 'docetaxel', 'carboplatin'}, {'doxorubicin', 'trastuzumab', 'pertuzumab', 'cyclophosphamide', 'paclitaxel'}, {'docetaxel', 'epirubicin', 'trastuzumab', 'pertuzumab', 'cyclophosphamide', 'fluorouracil'}]\n",
      "9\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is a her2/neu receptor antagonist indicated for the treatment of her2 -overexpressing breast cancer. select patients for therapy based on an fda-approved companion diagnostic for herceptin. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early-stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is neratinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: nerlynx is a kinase inhibitor indicated as a single agent, for the extended adjuvant treatment of adult patients with early-stage her2-positive breast cancer, to follow adjuvant trastuzumab based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + doxorubicin + fluorouracil + docetaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + carboplatin + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + taxane-based chemotherapy + her2 inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + doxorubicin + docetaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + doxorubicin + fluorouracil + paclitaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"invasive breast carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"early stage\",\n",
      "        \"Drug Name\": \"trastuzumab + fluorouracil + docetaxel + pertuzumab + epirubicin + cyclophosphamide\",\n",
      "        \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "        \"Genomic Features\": \"her2-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"invasive breast carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"early stage\",\n",
      "        \"Drug Name\": \"neratinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"to follow adjuvant trastuzumab based therapy\",\n",
      "        \"Genomic Features\": \"her2-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"invasive breast carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"early stage\",\n",
      "        \"Drug Name\": \"trastuzumab + docetaxel + pertuzumab + epirubicin + cyclophosphamide\",\n",
      "        \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "        \"Genomic Features\": \"her2-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 4\": {\n",
      "        \"Disease Name\": \"invasive breast carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"early stage\",\n",
      "        \"Drug Name\": \"trastuzumab + doxorubicin + fluorouracil + docetaxel + pertuzumab + cyclophosphamide\",\n",
      "        \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "        \"Genomic Features\": \"her2-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 5\": {\n",
      "        \"Disease Name\": \"invasive breast carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"early stage\",\n",
      "        \"Drug Name\": \"trastuzumab + fluorouracil + paclitaxel + pertuzumab + epirubicin + cyclophosphamide\",\n",
      "        \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "        \"Genomic Features\": \"her2-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 6\": {\n",
      "        \"Disease Name\": \"invasive breast carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"early stage\",\n",
      "        \"Drug Name\": \"trastuzumab + carboplatin + docetaxel + pertuzumab\",\n",
      "        \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "        \"Genomic Features\": \"her2-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 7\": {\n",
      "        \"Disease Name\": \"invasive breast carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"early stage\",\n",
      "        \"Drug Name\": \"trastuzumab + paclitaxel + pertuzumab + epirubicin + cyclophosphamide\",\n",
      "        \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "        \"Genomic Features\": \"her2-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 8\": {\n",
      "        \"Disease Name\": \"invasive breast carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"early stage\",\n",
      "        \"Drug Name\": \"trastuzumab + doxorubicin + docetaxel + pertuzumab + cyclophosphamide\",\n",
      "        \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "        \"Genomic Features\": \"her2-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 9\": {\n",
      "        \"Disease Name\": \"invasive breast carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"early stage\",\n",
      "        \"Drug Name\": \"trastuzumab + doxorubicin + fluorouracil + paclitaxel + pertuzumab + cyclophosphamide\",\n",
      "        \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "        \"Genomic Features\": \"her2-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with acute myeloid leukemia cancer has idh1 p.r132s, what therapy is recommended?\n",
      "[{'ivosidenib'}, {'ivosidenib', 'azacitidine'}]\n",
      "2\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r140g, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r140q, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r140w, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r172w, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r172g, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r172s, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'If a patient with acute myeloid leukemia cancer has idh1 p.r132s, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'If a patient with acute myeloid leukemia cancer has idh1 p.r132c, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r140l, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r172m, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with acute myeloid leukemia cancer has idh1 p.r132s, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Newly diagnosed in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy\",\n",
      "        \"Drug Name\": \"Ivosidenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"idh1 p.r132s\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?\n",
      "[{'asciminib'}, {'bosutinib'}, {'bosutinib'}, {'dasatinib'}, {'dasatinib'}, {'imatinib'}, {'imatinib'}, {'nilotinib'}, {'asciminib'}]\n",
      "9\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has abl1 p.t315i, bcr::abl1, one recommended therapy is asciminib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: scemblix is a kinase inhibitor indicated for the treatment of adult patients with ph+ cml in cp with the t315i mutation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, one recommended therapy is bosutinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: bosulif is a kinase inhibitor indicated for the treatment of adult patients with accelerated, or blast phase ph+ cml with resistance or intolerance to prior therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf', 'If a patient with philadelphia chromosome-positive acute lymphoid leukemia cancer has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, one recommended therapy is bosutinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: bosulif is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with chronic phase ph+ chronic myelogenous leukemia (cml), newly-diagnosed or resistant or intolerant to prior therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in blast crisis (bc), accelerated phase (ap), or in chronic phase (cp) after failure of interferon-alpha therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in blast crisis (bc), accelerated phase (ap), or in chronic phase (cp) after failure of interferon-alpha therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, one recommended therapy is asciminib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: scemblix is a kinase inhibitor indicated for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'If a patient with philadelphia chromosome-positive acute lymphoid leukemia cancer has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) in combination with chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Philadelphia chromosome-positive chronic myelogenous leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Chronic phase (CP), accelerated phase (AP), or blast crisis (BC)\",\n",
      "        \"Drug Name\": \"Imatinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"After failure of interferon-alpha therapy\",\n",
      "        \"Genomic Features\": \"bcr::abl1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Philadelphia chromosome-positive chronic myelogenous leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Chronic phase (CP)\",\n",
      "        \"Drug Name\": \"Imatinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"bcr::abl1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Philadelphia chromosome-positive chronic myelogenous leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Chronic phase (CP)\",\n",
      "        \"Drug Name\": \"Asciminib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Previously treated\",\n",
      "        \"Genomic Features\": \"bcr::abl1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 4\": {\n",
      "        \"Disease Name\": \"Philadelphia chromosome-positive chronic myelogenous leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Chronic phase (CP)\",\n",
      "        \"Drug Name\": \"Bosutinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed or resistant or intolerant to prior therapy\",\n",
      "        \"Genomic Features\": \"bcr::abl1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?\n",
      "[{'abemaciclib', 'anastrozole'}, {'abemaciclib', 'letrozole'}, {'abemaciclib', 'fulvestrant'}, {'abemaciclib'}, {'ribociclib', 'fulvestrant'}, {'fulvestrant', 'palbociclib'}, {'abemaciclib', 'fulvestrant'}, {'palbociclib', 'letrozole'}, {'fulvestrant', 'palbociclib'}, {'ribociclib', 'anastrozole'}, {'ribociclib', 'letrozole'}, {'ribociclib', 'fulvestrant'}]\n",
      "12\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is a her2/neu receptor antagonist indicated for the treatment of her2 -overexpressing breast cancer. select patients for therapy based on an fda-approved companion diagnostic for herceptin. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf', 'If a patient with metastatic invasive breast carcinoma cancer has her2-positive, one recommended therapy is eribulin + margetuximab. therapy type: chemotherapy + hormone therapy. therapy strategy: tubulin polymerization inhibition + her2 inhibition. indication: margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf', 'If a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, one recommended therapy is abemaciclib. therapy type: targeted therapy. therapy strategy: cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with unresectable or metastatic invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic her2-positive (ihc 3+ or ish positive) breast cancer who have received a prior anti-her2-based regimen either (i) in the metastatic setting, or (ii) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with early-stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is neratinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: nerlynx is a kinase inhibitor indicated as a single agent, for the extended adjuvant treatment of adult patients with early-stage her2-positive breast cancer, to follow adjuvant trastuzumab based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Invasive Breast Carcinoma Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n",
      "        \"Drug Name\": \"Abemaciclib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Disease progression following endocrine therapy and prior chemotherapy in the metastatic setting\",\n",
      "        \"Genomic Features\": \"HER2-negative, ER-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Invasive Breast Carcinoma Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n",
      "        \"Drug Name\": \"Anastrozole + Abemaciclib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Initial endocrine-based therapy\",\n",
      "        \"Genomic Features\": \"HER2-negative, ER-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Invasive Breast Carcinoma Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n",
      "        \"Drug Name\": \"Abemaciclib + Letrozole\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Initial endocrine-based therapy\",\n",
      "        \"Genomic Features\": \"HER2-negative, ER-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?\n",
      "[{'abemaciclib', 'tamoxifen'}, {'abemaciclib', 'letrozole'}, {'ribociclib', 'goserelin', 'anastrozole'}, {'ribociclib', 'goserelin', 'letrozole'}, {'abemaciclib', 'anastrozole'}, {'exemestane', 'abemaciclib'}]\n",
      "6\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is a her2/neu receptor antagonist indicated for the treatment of her2 -overexpressing breast cancer. select patients for therapy based on an fda-approved companion diagnostic for herceptin. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early-stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is neratinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: nerlynx is a kinase inhibitor indicated as a single agent, for the extended adjuvant treatment of adult patients with early-stage her2-positive breast cancer, to follow adjuvant trastuzumab based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf', 'If a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + carboplatin + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + taxane-based chemotherapy + her2 inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, er positive, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + doxorubicin + fluorouracil + docetaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Early Invasive Breast Carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"PR Positive, HER2-Negative, ER Positive\",\n",
      "        \"Drug Name\": \"Abemaciclib + Letrozole\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Node Positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?\n",
      "[{'carboplatin', 'paclitaxel', 'nivolumab'}, {'durvalumab', 'paclitaxel', 'carboplatin'}, {'durvalumab', 'gemcitabine', 'cisplatin'}, {'durvalumab', 'pemetrexed', 'cisplatin'}, {'durvalumab', 'pemetrexed', 'carboplatin'}, {'pemetrexed', 'cisplatin', 'nivolumab'}, {'gemcitabine', 'cisplatin', 'nivolumab'}, {'carboplatin', 'ipilimumab', 'pemetrexed', 'nivolumab'}, {'pemetrexed', 'ipilimumab', 'cisplatin', 'nivolumab'}, {'carboplatin', 'ipilimumab', 'paclitaxel', 'nivolumab'}]\n",
      "10\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with metastatic non-squamous non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + pemetrexed + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antifolate + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous nsclc, with no egfr or alk genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'If a patient with metastatic non-squamous non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is pemetrexed + cisplatin + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: antifolate + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous nsclc, with no egfr or alk genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'If a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, pd-l1 >= 1%, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated as a single agent for the first-line treatment of patients with nsclc expressing pd-l1 [tumor proportion score (tps) >=1%] as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations, and is: stage iii where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'If a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + gemcitabine + cisplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + antimetabolite + platinum-based chemotherapy. indication: opdivo is a programmed death receptor-1 (pd-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known egfr mutations or alk rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent opdivo as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'If a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + pemetrexed + cisplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: opdivo is a programmed death receptor-1 (pd-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known egfr mutations or alk rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent opdivo as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'If a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + gemcitabine + cisplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + antimetabolite + platinum-based chemotherapy. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'If a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + pemetrexed + cisplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'If a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + carboplatin + durvalumab + pemetrexed. therapy type: immunotherapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition + antifolate. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'If a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + carboplatin + durvalumab + gemcitabine. therapy type: immunotherapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition + antimetabolite. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'If a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + ipilimumab + pemetrexed + cisplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition + antifolate + platinum-based chemotherapy. indication: opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no egfr or alk genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Resectable (tumors >=4 cm or node positive)\",\n",
      "        \"Drug Name\": \"Nivolumab + Gemcitabine + Cisplatin\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"Wild type EGFR, Wild type ALK\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Resectable (tumors >=4 cm or node positive)\",\n",
      "        \"Drug Name\": \"Nivolumab + Pemetrexed + Cisplatin\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"Wild type EGFR, Wild type ALK\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic or Recurrent\",\n",
      "        \"Drug Name\": \"Nivolumab + Ipilimumab + Pemetrexed + Cisplatin\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"Wild type EGFR, Wild type ALK\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?\n",
      "[{'exemestane', 'everolimus'}, {'fulvestrant'}, {'datopotamab deruxtecan'}]\n",
      "3\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is a her2/neu receptor antagonist indicated for the treatment of her2 -overexpressing breast cancer. select patients for therapy based on an fda-approved companion diagnostic for herceptin. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf', 'If a patient with metastatic invasive breast carcinoma cancer has her2-positive, one recommended therapy is eribulin + margetuximab. therapy type: chemotherapy + hormone therapy. therapy strategy: tubulin polymerization inhibition + her2 inhibition. indication: margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early-stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is neratinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: nerlynx is a kinase inhibitor indicated as a single agent, for the extended adjuvant treatment of adult patients with early-stage her2-positive breast cancer, to follow adjuvant trastuzumab based therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early invasive breast carcinoma cancer has her2-negative, er positive, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with invasive breast carcinoma cancer has her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + carboplatin + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + taxane-based chemotherapy + her2 inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Invasive Breast Carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n",
      "        \"Drug Name\": \"Datopotamab Deruxtecan\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease\",\n",
      "        \"Genomic Features\": \"HER2-negative, ER-positive\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?\n",
      "[{'abemaciclib', 'anastrozole'}, {'abemaciclib', 'letrozole'}, {'abemaciclib', 'fulvestrant'}, {'abemaciclib'}, {'ribociclib', 'fulvestrant'}, {'fulvestrant', 'palbociclib'}, {'abemaciclib', 'fulvestrant'}, {'palbociclib', 'letrozole'}, {'fulvestrant', 'palbociclib'}, {'ribociclib', 'anastrozole'}, {'ribociclib', 'letrozole'}, {'ribociclib', 'fulvestrant'}]\n",
      "12\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is a her2/neu receptor antagonist indicated for the treatment of her2 -overexpressing breast cancer. select patients for therapy based on an fda-approved companion diagnostic for herceptin. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf', 'If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is abemaciclib. therapy type: targeted therapy. therapy strategy: cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + carboplatin + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + taxane-based chemotherapy + her2 inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + doxorubicin + fluorouracil + docetaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with metastatic invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and docetaxel for treatment of patients with her2-positive metastatic breast cancer (mbc) who have not received prior anti-her2 therapy or chemotherapy for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Invasive Breast Carcinoma Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n",
      "        \"Drug Name\": \"Abemaciclib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Disease progression following endocrine therapy and prior chemotherapy in the metastatic setting\",\n",
      "        \"Genomic Features\": \"PR positive, HER2-negative\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Invasive Breast Carcinoma Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n",
      "        \"Drug Name\": \"Abemaciclib + Letrozole\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Initial endocrine-based therapy\",\n",
      "        \"Genomic Features\": \"PR positive, HER2-negative\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132l, what therapy is recommended?\n",
      "[{'ivosidenib'}, {'olutasidenib'}]\n",
      "2\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132g, one recommended therapy is olutasidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: rezlidhia is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with a susceptible idh1 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132l, one recommended therapy is olutasidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: rezlidhia is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with a susceptible idh1 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132c, one recommended therapy is olutasidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: rezlidhia is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with a susceptible idh1 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132s, one recommended therapy is olutasidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: rezlidhia is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with a susceptible idh1 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132h, one recommended therapy is olutasidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: rezlidhia is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with a susceptible idh1 mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r140g, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r140w, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r172w, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r140q, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'If a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r140l, one recommended therapy is enasidenib. therapy type: targeted therapy. therapy strategy: idh2 inhibition. indication: idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132l, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"acute myeloid leukemia\",\n",
      "        \"Disease Phase or Condition\": \"relapsed or refractory\",\n",
      "        \"Drug Name\": \"olutasidenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"relapsed or refractory\",\n",
      "        \"Genomic Features\": \"idh1 p.r132l\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with unresectable or metastatic melanoma cancer has braf p.v600e, what therapy is recommended?\n",
      "[{'vemurafenib', 'atezolizumab', 'cobimetinib'}, {'encorafenib', 'binimetinib'}, {'vemurafenib', 'cobimetinib'}, {'dabrafenib'}, {'dabrafenib', 'trametinib'}, {'encorafenib', 'binimetinib'}, {'trametinib'}, {'dabrafenib', 'trametinib'}, {'vemurafenib'}]\n",
      "9\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with unresectable or metastatic melanoma cancer has braf p.v600e, one recommended therapy is vemurafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: zelboraf is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf', 'If a patient with unresectable or metastatic melanoma cancer has braf p.v600e, one recommended therapy is dabrafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: tafinlar is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf', 'If a patient with unresectable or metastatic melanoma cancer has braf p.v600e, one recommended therapy is binimetinib + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda-approved test. braftovi is not indicated for treatment of patients with wild-type braf melanoma, wild-type braf crc, or wild-type braf nsclc. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf', 'If a patient with unresectable or metastatic melanoma cancer has braf p.v600e, one recommended therapy is binimetinib + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf', 'If a patient with unresectable or metastatic melanoma cancer has braf p.v600e, one recommended therapy is vemurafenib + cobimetinib + atezolizumab. therapy type: targeted therapy + targeted therapy + immunotherapy. therapy strategy: b-raf inhibition + mek inhibition + pd-1/pd-l1 inhibition. indication: tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with braf v600 mutation-positive unresectable or metastatic melanoma. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf', 'If a patient with unresectable or metastatic melanoma cancer has braf p.v600k, one recommended therapy is binimetinib + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda-approved test. braftovi is not indicated for treatment of patients with wild-type braf melanoma, wild-type braf crc, or wild-type braf nsclc. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf', 'If a patient with unresectable or metastatic melanoma cancer has braf p.v600e, one recommended therapy is vemurafenib + cobimetinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: cotellic is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, in combination with vemurafenib. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf', 'If a patient with unresectable or metastatic melanoma cancer has braf p.v600k, one recommended therapy is vemurafenib + cobimetinib + atezolizumab. therapy type: targeted therapy + targeted therapy + immunotherapy. therapy strategy: b-raf inhibition + mek inhibition + pd-1/pd-l1 inhibition. indication: tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with braf v600 mutation-positive unresectable or metastatic melanoma. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf', 'If a patient with unresectable or metastatic melanoma cancer has braf p.v600k, one recommended therapy is binimetinib + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf', 'If a patient with unresectable or metastatic melanoma cancer has braf p.v600e, one recommended therapy is trametinib. therapy type: targeted therapy. therapy strategy: mek inhibition. indication: mekinist is a kinase inhibitor indicated as a single agent for the treatment of braf-inhibitor treatment-naive patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fda-approved test. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with unresectable or metastatic melanoma cancer has braf p.v600e, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Melanoma\",\n",
      "        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n",
      "        \"Drug Name\": \"Vemurafenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRAF V600E\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Melanoma\",\n",
      "        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n",
      "        \"Drug Name\": \"Dabrafenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRAF V600E\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Melanoma\",\n",
      "        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n",
      "        \"Drug Name\": \"Binimetinib + Encorafenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRAF V600E or V600K\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 4\": {\n",
      "        \"Disease Name\": \"Melanoma\",\n",
      "        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n",
      "        \"Drug Name\": \"Binimetinib + Encorafenib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRAF V600E or V600K\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 5\": {\n",
      "        \"Disease Name\": \"Melanoma\",\n",
      "        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n",
      "        \"Drug Name\": \"Vemurafenib + Cobimetinib + Atezolizumab\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRAF V600\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 6\": {\n",
      "        \"Disease Name\": \"Melanoma\",\n",
      "        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n",
      "        \"Drug Name\": \"Vemurafenib + Cobimetinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRAF V600E or V600K\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 7\": {\n",
      "        \"Disease Name\": \"Melanoma\",\n",
      "        \"Disease Phase or Condition\": \"Unresectable or Metastatic\",\n",
      "        \"Drug Name\": \"Trametinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"BRAF-inhibitor treatment-naive\",\n",
      "        \"Genomic Features\": \"BRAF V600E or V600K\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?\n",
      "[{'abemaciclib', 'anastrozole'}, {'abemaciclib', 'letrozole'}, {'abemaciclib', 'fulvestrant'}, {'abemaciclib'}, {'ribociclib', 'fulvestrant'}, {'fulvestrant', 'palbociclib'}, {'abemaciclib', 'fulvestrant'}, {'palbociclib', 'letrozole'}, {'fulvestrant', 'palbociclib'}, {'ribociclib', 'anastrozole'}, {'ribociclib', 'letrozole'}, {'ribociclib', 'fulvestrant'}]\n",
      "12\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is a her2/neu receptor antagonist indicated for the treatment of her2 -overexpressing breast cancer. select patients for therapy based on an fda-approved companion diagnostic for herceptin. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf', 'If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, one recommended therapy is abemaciclib. therapy type: targeted therapy. therapy strategy: cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is abemaciclib. therapy type: targeted therapy. therapy strategy: cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + fluorouracil + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with metastatic invasive breast carcinoma cancer has her2-positive, one recommended therapy is eribulin + margetuximab. therapy type: chemotherapy + hormone therapy. therapy strategy: tubulin polymerization inhibition + her2 inhibition. indication: margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'If a patient with early stage invasive breast carcinoma cancer has her2-positive, one recommended therapy is trastuzumab + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is a her2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Advanced or Metastatic Invasive Breast Carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"PR Positive, HER2-Negative, ER Positive\",\n",
      "        \"Drug Name\": \"Abemaciclib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Disease progression following endocrine therapy and prior chemotherapy in the metastatic setting\",\n",
      "        \"Genomic Features\": \"HR-Positive, HER2-Negative\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Advanced or Metastatic Invasive Breast Carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"PR Positive, HER2-Negative, ER Positive\",\n",
      "        \"Drug Name\": \"Anastrozole + Abemaciclib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Initial endocrine-based therapy\",\n",
      "        \"Genomic Features\": \"HR-Positive, HER2-Negative\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Advanced or Metastatic Invasive Breast Carcinoma\",\n",
      "        \"Disease Phase or Condition\": \"PR Positive, HER2-Negative, ER Positive\",\n",
      "        \"Drug Name\": \"Abemaciclib + Letrozole\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Initial endocrine-based therapy\",\n",
      "        \"Genomic Features\": \"HR-Positive, HER2-Negative\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?\n",
      "[{'asciminib'}, {'bosutinib'}, {'bosutinib'}, {'dasatinib'}, {'dasatinib'}, {'imatinib'}, {'imatinib'}, {'nilotinib'}, {'asciminib'}]\n",
      "9\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has abl1 p.t315i, bcr::abl1, one recommended therapy is asciminib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: scemblix is a kinase inhibitor indicated for the treatment of adult patients with ph+ cml in cp with the t315i mutation. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, one recommended therapy is bosutinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: bosulif is a kinase inhibitor indicated for the treatment of adult patients with accelerated, or blast phase ph+ cml with resistance or intolerance to prior therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf', 'If a patient with philadelphia chromosome-positive acute lymphoid leukemia cancer has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, one recommended therapy is bosutinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: bosulif is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with chronic phase ph+ chronic myelogenous leukemia (cml), newly-diagnosed or resistant or intolerant to prior therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in blast crisis (bc), accelerated phase (ap), or in chronic phase (cp) after failure of interferon-alpha therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in blast crisis (bc), accelerated phase (ap), or in chronic phase (cp) after failure of interferon-alpha therapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, one recommended therapy is asciminib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: scemblix is a kinase inhibitor indicated for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp). approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'If a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'If a patient with philadelphia chromosome-positive acute lymphoid leukemia cancer has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: gleevec is a kinase inhibitor indicated for the treatment of pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) in combination with chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Philadelphia chromosome-positive chronic myelogenous leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Chronic phase (CP), accelerated phase (AP), or blast crisis (BC)\",\n",
      "        \"Drug Name\": \"Imatinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"After failure of interferon-alpha therapy\",\n",
      "        \"Genomic Features\": \"bcr::abl1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Philadelphia chromosome-positive chronic myelogenous leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Chronic phase (CP)\",\n",
      "        \"Drug Name\": \"Imatinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed\",\n",
      "        \"Genomic Features\": \"bcr::abl1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Philadelphia chromosome-positive chronic myelogenous leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Chronic phase (CP)\",\n",
      "        \"Drug Name\": \"Bosutinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Newly diagnosed or resistant or intolerant to prior therapy\",\n",
      "        \"Genomic Features\": \"bcr::abl1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 4\": {\n",
      "        \"Disease Name\": \"Philadelphia chromosome-positive chronic myelogenous leukemia\",\n",
      "        \"Disease Phase or Condition\": \"Chronic phase (CP)\",\n",
      "        \"Drug Name\": \"Asciminib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Previously treated\",\n",
      "        \"Genomic Features\": \"bcr::abl1\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n",
      "if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?\n",
      "[{'carboplatin', 'paclitaxel', 'nivolumab'}, {'durvalumab', 'paclitaxel', 'carboplatin'}, {'durvalumab', 'gemcitabine', 'cisplatin'}, {'durvalumab', 'pemetrexed', 'cisplatin'}, {'durvalumab', 'pemetrexed', 'carboplatin'}, {'pemetrexed', 'cisplatin', 'nivolumab'}, {'gemcitabine', 'cisplatin', 'nivolumab'}, {'carboplatin', 'ipilimumab', 'pemetrexed', 'nivolumab'}, {'pemetrexed', 'ipilimumab', 'cisplatin', 'nivolumab'}, {'carboplatin', 'ipilimumab', 'paclitaxel', 'nivolumab'}]\n",
      "10\n",
      "\n",
      "        Context information is below.\n",
      "        ---------------------\n",
      "        ['If a patient with metastatic non-squamous non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + pemetrexed + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antifolate + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous nsclc, with no egfr or alk genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'If a patient with metastatic non-squamous non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is pemetrexed + cisplatin + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: antifolate + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous nsclc, with no egfr or alk genomic tumor aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'If a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, pd-l1 >= 1%, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated as a single agent for the first-line treatment of patients with nsclc expressing pd-l1 [tumor proportion score (tps) >=1%] as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations, and is: stage iii where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf', 'If a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + gemcitabine + cisplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + antimetabolite + platinum-based chemotherapy. indication: opdivo is a programmed death receptor-1 (pd-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known egfr mutations or alk rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent opdivo as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'If a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + pemetrexed + cisplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: opdivo is a programmed death receptor-1 (pd-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known egfr mutations or alk rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent opdivo as adjuvant treatment after surgery. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'If a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + gemcitabine + cisplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + antimetabolite + platinum-based chemotherapy. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'If a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + pemetrexed + cisplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'If a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + carboplatin + durvalumab + pemetrexed. therapy type: immunotherapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition + antifolate. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'If a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + carboplatin + durvalumab + gemcitabine. therapy type: immunotherapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition + antimetabolite. indication: imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) genomic aberrations. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'If a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + ipilimumab + pemetrexed + cisplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition + antifolate + platinum-based chemotherapy. indication: opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no egfr or alk genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf']\n",
      "        ---------------------\n",
      "        Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?\n",
      "     \n",
      "        \n",
      "```json\n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Resectable (tumors >=4 cm or node positive)\",\n",
      "        \"Drug Name\": \"Nivolumab + Gemcitabine + Cisplatin\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Neoadjuvant treatment, followed by single-agent Opdivo as adjuvant treatment after surgery\",\n",
      "        \"Genomic Features\": \"Wild type EGFR, Wild type ALK\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Resectable (tumors >=4 cm or node positive)\",\n",
      "        \"Drug Name\": \"Nivolumab + Pemetrexed + Cisplatin\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Neoadjuvant treatment, followed by single-agent Opdivo as adjuvant treatment after surgery\",\n",
      "        \"Genomic Features\": \"Wild type EGFR, Wild type ALK\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic or Recurrent\",\n",
      "        \"Drug Name\": \"Nivolumab + Ipilimumab + Pemetrexed + Cisplatin\",\n",
      "        \"Prior Treatment or Resistance Status\": \"First-line treatment\",\n",
      "        \"Genomic Features\": \"Wild type EGFR, Wild type ALK\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 4\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Tremelimumab + Durvalumab + Gemcitabine + Cisplatin\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"Wild type EGFR, Wild type ALK\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\"\n",
      "    },\n",
      "    \"Treatment 5\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Tremelimumab + Durvalumab + Pemetrexed + Cisplatin\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"Wild type EGFR, Wild type ALK\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\"\n",
      "    },\n",
      "    \"Treatment 6\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Tremelimumab + Carboplatin + Durvalumab + Pemetrexed\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"Wild type EGFR, Wild type ALK\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\"\n",
      "    },\n",
      "    \"Treatment 7\": {\n",
      "        \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic\",\n",
      "        \"Drug Name\": \"Tremelimumab + Carboplatin + Durvalumab + Gemcitabine\",\n",
      "        \"Prior Treatment or Resistance Status\": \"None specified\",\n",
      "        \"Genomic Features\": \"Wild type EGFR, Wild type ALK\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf\"\n",
      "    }\n",
      "}\n",
      "```\n"
     ]
    }
   ],
   "source": [
    "num_true_drugs_list = []\n",
    "cancer_types = []\n",
    "biomarkers = []\n",
    "for i, row in standardized_to_raw_mapping_subset.reset_index(drop=True)[~np.array(output_eval['exact_match_acc'])].iterrows():\n",
    "    print(row['prompt'])\n",
    "    print(synthetic_query_answer_pair_dict[row['prompt']])\n",
    "    num_true_drugs_list.append(len(synthetic_query_answer_pair_dict[row['prompt']]))\n",
    "    print(len(synthetic_query_answer_pair_dict[row['prompt']]))\n",
    "    print(output_res['input prompt'][0][i])\n",
    "    print(output_res['full output'][0][i])\n",
    "    cancer_types.append(row['standardized_cancer'])\n",
    "    biomarkers.append(row['biomarker'])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "8a920abe",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[6, 12, 5, 5, 9, 2, 9, 12, 6, 10, 3, 12, 2, 9, 12, 9, 10]\n",
      "2\n",
      "7.823529411764706\n",
      "9.0\n",
      "12\n"
     ]
    }
   ],
   "source": [
    "print(num_true_drugs_list)\n",
    "print(np.min(num_true_drugs_list))\n",
    "print(np.mean(num_true_drugs_list))\n",
    "print(np.median(num_true_drugs_list))\n",
    "print(np.max(num_true_drugs_list))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "id": "e35e0c50",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('Invasive Breast Carcinoma', 8),\n",
       " ('Non-Small Cell Lung Cancer', 3),\n",
       " ('Acute Myeloid Leukemia', 2),\n",
       " ('Chronic Myelogenous Leukemia', 2),\n",
       " ('Prostate Adenocarcinoma', 1),\n",
       " ('Melanoma', 1)]"
      ]
     },
     "execution_count": 79,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Counter(cancer_types).most_common()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "b715732d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(\"['HER2-negative', 'ER positive']\", 3),\n",
       " (\"['PR positive', 'HER2-negative']\", 2),\n",
       " (\"['BCR::ABL1']\", 2),\n",
       " (\"['PR positive', 'HER2-negative', 'ER positive']\", 2),\n",
       " (\"['Wild type EGFR', 'Wild type ALK']\", 2),\n",
       " (\"['BRCA2 oncogenic variants']\", 1),\n",
       " (\"['EGFR Exon 19 (Deletion)']\", 1),\n",
       " (\"['HER2-positive']\", 1),\n",
       " (\"['IDH1 p.R132S']\", 1),\n",
       " (\"['IDH1 p.R132L']\", 1),\n",
       " (\"['BRAF p.V600E']\", 1)]"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Counter(biomarkers).most_common()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b0b77381",
   "metadata": {},
   "source": [
    "Here is what I think is happening:\n",
    "- in many of these exact match failed cases, there are many ground-truth drugs linked to their queries, so there's inherently high chance to miss some of the ground-truth drugs\n",
    "- many of these cases are associated with breast, lung, and leukemia\n",
    "- many of these cases are associated with HER2-negative, ER positive, PR positive status and BCR::ABL2 variant\n",
    "- some retrieved chunks do not have either exactly matching specific cancer type (i.e., the modifier/disease stage) or the gene biomarker (i.e., missing one of the queried biomarkers or a similar but different gene)\n",
    "- all these cases have been seen in our previous study, and can be handled by the rule-based retrieval approach (e.g., entity matching) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4a07ca3b",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
